1
Status: Approved ,  Date: 17 July 2020Janssen Research & Development *
Clinical Protocol
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration -
Resistant Prostate Cancer and DNA -Repair Anomalies
Protocol 64091742PCR2001: The Galahad Study; Phase 2
AMENDMENT 8
JNJ-64091742 (niraparib)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, 
BV; Janssen- Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland 
UC; Janssen Biopharma Inc.; or Janssen Research & Development, LLC. The term “sponsor” is used 
throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact 
[CONTACT_7171] p age that accompanies the protocol.
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312).
EudraCT NUMBER: 2016 -002057 -38
Status: Approved
Date: 17July 2020
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number: EDMS- ERI-123250857, 11.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements.
Confidentiality Statement
The information in this document contains trad e secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the info rmation is privileged or confidential and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confidential.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
2
Approved , Date: [ADDRESS_1044430] OF IN -TEXT T ABLES.......................................................................................................................... 4
PROTOCOL A MENDMENTS ....................................................................................................................... 6
SYNOPSIS .................................................................................................................................................. 28
TIME AND EVENTS SCHE DULE .............................................................................................................. 32
ABBREVIA TIONS ...................................................................................................................................... 35
1. INTRODUCTION ................................................................................................................................ 37
1.1. Background and Design Rationale ................................................................................................ 37
1.2. Summary  of Available Nonclinical and Clinical Data ..................................................................... 38
1.3. Benefit/Risk Assessment ............................................................................................................... 39
2. OBJECTIVES, ENDPOINT S/ASSESSMENTS, A ND HYPOTHESIS ............................................... 40
2.1. Objectives and Endpoints/Assessments ........................................................................................ [ADDRESS_1044431] POPUL ATION.................................................................................................................. 42
4.1. Prescreening Eligibility Criteria ...................................................................................................... 42
4.2. Inclusion Criteria ............................................................................................................................ 43
4.3. Exclusion Criteria ........................................................................................................................... 45
5. TREA TMENT A LLOCA TION AND BLINDING ................................................................................. 46
6. DOSA GE A ND A DMINISTR ATION.................................................................................................. 47
6.1. Study Drug Administration ............................................................................................................. 47
6.2. Dose Modification and Management of Toxicity ............................................................................ 47
6.2.1. Non-hematologic Toxicities ......................................................................................................... 47
[IP_ADDRESS]. Hepatic Toxicities .................................................................................................................... 48
6.2.2. Hematologic Toxicities ................................................................................................................ 48
6.3. Treatment Interruptions for Planned Procedures ........................................................................... 49
7. TREA TMENT COMPLIA NCE ............................................................................................................ 50
8. CONCOMIT ANT THERA PY.............................................................................................................. 50
8.1. Prohibited Concomitant Medications ............................................................................................. 50
8.2. Restricted Concomitant Medications ............................................................................................. 50
9. STUDY EVA LUATIONS .................................................................................................................... 51
9.1. Study Procedures ........................................................................................................................... 51
9.1.1. Overview ..................................................................................................................................... 51
9.1.2. Prescreening Phase for Biomarker Evaluation ........................................................................... 51
9.1.3. Screening Phase ........................................................................................................................ 51
9.1.4. Treatment Phase ........................................................................................................................ 52
9.1.5. End-of-Treatment Visit ................................................................................................................ 52
9.1.6. Follow -up Phase ......................................................................................................................... 53
9.1.7. Long- term Extension Phase ....................................................................................................... 53
9.2. Efficacy ........................................................................................................................................... 53
9.2.1. Evaluations ................................................................................................................................ .53
9.2.2. Endpoint Criteria ......................................................................................................................... 53
9.3. Pharmacokinetics ........................................................................................................................... 54
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
3
Approved , Date: [ADDRESS_1044432]-P ....................................................................................................................................... 56
9.4.3. EQ-5D-5L.................................................................................................................................... 56
9.5. Pharmacodynamics ........................................................................................................................ 56
9.6. Pharmacokinetic/Pharmacodynamic Evaluations .......................................................................... 56
9.7. Biom arkers ..................................................................................................................................... 56
9.7.1. Evaluations ................................................................................................................................ .57
[IP_ADDRESS]. Tissue Analysis ........................................................................................................................ 57
[IP_ADDRESS]. Circulating Tumor Cells ........................................................................................................... 57
[IP_ADDRESS]. Whole Blood for RNA .............................................................................................................. 57
[IP_ADDRESS]. Circulating Tumor DNA ............................................................................................................ 57
[IP_ADDRESS]. Saliva Testing .......................................................................................................................... [ADDRESS_1044433] COMPLETION/W ITHDRA WAL....................................................................................... 60
10.1. Discontinuation of Study Treatment ............................................................................................... 60
10.2. Withdrawal from the Study ............................................................................................................. 61
10.3. Withdrawal From the Use of Samples in Future Research ............................................................ 61
11. STATISTICA L METHODS ................................................................................................................. 62
11.1. Analysis Populations ...................................................................................................................... 62
11.2. Sample Size Determination ........................................................................................................... 62
11.3. Efficacy  Analyses ........................................................................................................................... 63
11.4. Pharmacokinetic Analy ses............................................................................................................. 63
11.5. Pharmacodynamic Analy ses.......................................................................................................... 63
11.6. Biom arker Analyses ....................................................................................................................... 63
11.7. Patient- reported Outcome Analyses .............................................................................................. 64
11.8. Pharmacokinetic/Pharmacodynamic Analyses .............................................................................. [ADDRESS_1044434] Quality ............................................................................ 71
14. STUDY DRUG INFORM ATION......................................................................................................... 71
14.1. Physical Description of Study Drug ................................................................................................ 71
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
4
Approved , Date: [ADDRESS_1044435] ................................................... 74
16.2.3. Informed Consent ....................................................................................................................... 75
16.2.4. Privacy of Personal Data ............................................................................................................ 76
16.2.5. Long- Term Retention of Samples for Additional Future Research ............................................ 77
16.2.6. Countr y Selection ....................................................................................................................... 77
17. ADM INISTRA TIVE REQUI REM ENTS .............................................................................................. 77
17.1. Protocol Amendments .................................................................................................................... 77
17.2. Regulatory Documentation ............................................................................................................ 78
17.2.1. Regulatory Approval/Notification ................................................................................................ [ADDRESS_1044436] Identification, Enrollment, and Screening Lo gs................................................................ 79
17.4. Source Documentation ................................................................................................................... 79
17.5. Case Report Form Completion ...................................................................................................... 80
17.6. Data Quality Assurance/Quality Control ........................................................................................ [ADDRESS_1044437] Retention ........................................................................................................................... 81
17.8. Monitoring ...................................................................................................................................... 81
17.9. Study Com pletion/Termination ....................................................................................................... 82
17.9.1. Study Com pletion/End of Study .................................................................................................. [ADDRESS_1044438] OF A TTACHMENTS
Attachment 1: Prostate Cancer W orking Group 3 Criteria ................................................................ .87
Attachment 2: Summary  of RECIST Criteria Version 1.1 with Integration of PCW G3 for 
Evaluation of Response .............................................................................................. 88
Attachment 3: ECOG Performance Status ........................................................................................ 95
Attachment 4: Medications That Could Potentially Cause QT Prolongation or Torsades De 
Pointes ........................................................................................................................ 96
Attachment 5: Substrates of CYP1A2 ................................................................................................ 97
Attachment 6: Anticipated Events ...................................................................................................... 98
Attachment 7: Long- term Extension Phase ..................................................................................... [ADDRESS_1044439] OF IN -TEXT TA BLES
TABLES
Table 1: Study Objectives and Endpoints/Assessments ........................................................................ 40
Table 2: Dose reduction for Drug -related Non -hematologic Toxicities ................................................... 48
Table 3: Dose Modification Criteria for AST/ALT/Bilirubin Abnormalities for Niraparib .......................... 48
Table 4: Dose Modification/Reductions for Hematologic Toxicity (Platelet Count and Neutrophil 
Count) ....................................................................................................................................... 49
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
5
Approved , Date: 17 July 2020Table 5: Biom arker Panel ................................................................................................ ....................... 56
Table 6: Study Treatment Administration for the Long -term Extension Phase .................................... 100
Table 7: Time and Events Schedule (Long- term Extension Phase With Lim ited Data Collection) ......101
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
6
Approved , Date: [ADDRESS_1044440] recent amendment.
Amendment 8(17July2020 )
The overall reason sfor the amendment: (1) to add a Long- term Extension Phase , (2) to include subjects who 
have germline pathogenic BRCA ( BRCA1 or BRCA2 )mutations in the efficacy analyses , and (3) to provide 
updated patient enrollment recruitment requirements .
Applicable Section(s) Description of Change(s)
Rationale: To allow  subjects who are benefiting from therapy to continue to receive niraparib after the primary 
analysis is completed .
Synopsis (Overview of 
Study Design);
Time and Events
Schedule;
3. Study Design;
9.1.7. Long -term 
Extension Phase;
10.2. Withdraw al from 
the Study;
16.2.3. Informed 
Consent;
Attachment 7Attachment 7 outlines the criteria for participation and procedures to be performed in 
the Long -term Extension Phase.
Added the option for remote/virtual consenting.
Rationale: To align the analysis population with the protocol entry criterion 7.2.b. that allow ssubjects with 
germline pathogenic BRCA1 or BRCA2 mutations to enroll .
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
7
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Synopsis (Objectives, 
Endpoints/Assessments, 
and Hypothesis, 
Overvie w of Study 
Design, Statistical 
Methods );
2.1. Objectives and 
Endpoints/Assessments;
3. Study Design;
9.7. Biomarkers ;
11.1. Analysis 
Populations;
11.3. Efficacy 
Analyses;Added text indicating that subjects w ho have germline pathogenic BRCA ( BRCA1 or 
BRCA2) mutations will be included in the efficacy analyses.
Rationale: The current number of planned subjects has been updated.
Synopsis (Overview of 
Study Design);
3. Study Design;
11.2. Sample Size 
DeterminationSpecified that the study will assess up to approximately [ADDRESS_1044441] 75 subjects with BRCA (BRCA1 or BRCA2) mutations and [ADDRESS_1044442] 90 subjects w ith  non -measurable disease will be included.
The sample size estimates were adjusted accordingly.
Rationale: To align w ith niraparib core safety inform ation.
6.2.1. Non -hematologic 
Toxicities
10.1. Discontinuation of 
Study TreatmentAdded t reatment -related hypertensive crisis or posterior reversible encephalopathy 
syndrome as conditions for which subject’s study treatment must be discontinued.
Rationale: To align w ith current internal protocol template.
12.3.4. Disease 
Progression and Death
Attachment 6: 
Anticipated EventsInstructions for reporting disease progression and death have been updated.
Instructions for reporting and assessing anticipated events have been updated.
COVID -19 Appendix (17 April 2020)
The overall reason for the appendix: to provide study -related guidance during the global coronavirus 
(COVID -19) pandemic .
Applicable Section(s) Description of Change(s)
Rationale: For health and safety reasons, subjects may not be able to come to the study site for scheduled 
procedures .
COVID -19 Appendix The standalone Appendix provides guidance to investigators for managing 
study -related procedures during the COVID -19 pandemic.
Amendment 7 (30October 2019)
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
8
Approved , Date: 17 July 2020The overall reason for the amendment: is to allow  subjects with local germline pathogenic results for Breast 
Cancer gene 1 ( BRCA1) or Breast Cancer gene 2 ( BRCA2) DNA -repair defects ( DRD )to enter the trial given the 
high likelihood of biallelic mutations .
Applicable Section(s) Description of Change(s)
Rationale: As the enrollment was nearing completion to the anticipated number for subjects with non -
measurable disease (irrespective of mutational status), the number of subjects with non -measurable disease was 
increased to allow  continued enrollment of such subjects up to an increased target number.
Synopsis (Overview 
of Study Design , 
Statistical Methods) ; 
3.Study Design ; 
11.2.Sample Size 
DeterminationMinor edits mad e to indicate the study will assess up to approximately 155 subjects with 
measurable disease who are biomarker -positive ( blood -or tissue -based assay), and at 
least 60 subjects w ith non -measurable disease, regardless of DNA  anomaly .
Rationale: Subject population clarified via notation of types of DNA -repair anomalies to allow  inclu sion of
subjects with local -test assessed germline pathogenic BRCA1 or BRCA2 mutations . Also include modifications 
to Prescreening Eligibility Criteria and Inclusion Criteria to align with previous Amendment that reflected the 
current clinical practice for the treatment of patients with metastatic prostate cancer based on protocol steering 
committee feedback and to reflect the characteristics of the third line mCRPC po pulation .
4. Subject Population Text was updated as follows (deletions appear in overstrike, new text in bold):
Male subjects over the age of 18 years with mCRPC and DNA -repair anomalies 
(biallelic mutations and germline pathogenic mutations only for BRC A1 or BRCA2 
mutations )who received aprior taxane -based chemotherapy and AR-targeted therapy
(second -generation or later )for the treatment of metastatic prostate cancer are eligible 
for the study.
4.1. Prescreening 
Eligibility Criteria
(Criterion 3.3)Text was updated as follows (deletions appear in overstrike, new text in bold):
Must have received or be currently on at least [ADDRESS_1044443] 1AR-
targeted (s econd -generation or later) therapy .
4.2. Inclusion Criteria 
(Criterion 6.5and 
7.2)Text was updated as follows (deletions appear in overstrike, new text in bold):
Received a second -generation or later AR-targeted therapy (for example, abiraterone 
acetate plus prednisone, enzalutamide, apalutamid e)for the treatment of metastatic 
prostate cancer w ith evidence of disease progression or non-metastatic castration -
resistant prostate cancer with evidence of subsequent metastasis .
Criterion 7.1 w as modified (now  noted as Criterion 7.2):
Biomarker -positive for DNA repair anomalies by [CONTACT_196351]
(Ssee Section 9.7):
a.Biallelic DNA -repair anomaly (refer toTable 5) based on a 
sponsor -validated blood or tissue assay .
b.Germline pathogenic BRCA1 or  BRCA2 by [CONTACT_762420] (somatic local results 
must be confirmed as positive by [CONTACT_456] -validated assay before 
dosing).
9.7. Biomarkers Text edited to characterize the primary efficacy population (ie, subjects confirmed to be 
biallelic BRCA1 or BRCA2 by a sponsor -validated blood -or tissue -based assay). 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
9
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
11.1. Analysis 
PopulationsText was updated as follows (deletions appear in overstrike, new text in bold):
Enrolled Population : All subjects who are enrolled into the study. This population will be 
used for exploring efficacy/anti -tumor activity , subject disposition and biom arker 
analyses.
Prim ary Efficacy ITTPopulation: All subjects who received at least [ADDRESS_1044444] biallelic BRCA1 or BRCA2 DNA repair anomalies as determined by a
per the sponsor -validated blood -or tissue -based assay. This population w ill be used for 
efficacy analyses.
Rationale: Revisions were made to rename [CONTACT_941] “ intent -to-treat (ITT )Population” as the “Primary Efficacy 
Population”; to define study phases, biomarker panel collection periods, samples for collection, timing of when 
subjects can enter the treatment phase, and criteria for biomarker -positi vity. 
Synopsis (Overview 
of Study Design ); 
3.Study DesignMinor modifications made to describe the 4 study phases.
Synopsis (Overview 
of Study Design ,
Subject Population );
4. Study PopulationMinor edits to text, including clarification of when subjects received taxane -based 
chemotherapy and androgen receptor ( AR)-targeted therapy .
Synopsis (Biom arker 
Evaluations )Minor edits made regarding the use of whole blood for RNA and circulating tumor 
DNA.
Time and Events 
ScheduleThe biomarker panel will be collected during either the Prescreening orScreening 
phases.
11.1. Analysis 
Populations; 
11.3. Efficacy 
PopulationsRenamed the ITT Population as the Primary Efficacy Population.
Time and Events
Schedule (Tablenotes 
b, c, and d )Text was updated as follows (deletions appear in overstrike, new text in bold):
b.Biomarker panel: Blood and tissue samples will be collected for evaluation of 
biomarker -positivity during the Prescreening or Screening Phase (see 
Sections 9.1.2. and 9.7.). Note that the sponsor’s tissue based assay (archival or 
recently collected) may also be used to determine eligibility (see Section 9.7for 
full details). Results obtained from  the sponsor- validated assays from  other 
Janssen -sponsored trials can be used to enter screening for this trial. 
Subjects who are positive for germline pathogenic BRCA1 or BRCA [ADDRESS_1044445] results (blood or saliva) and will be confirmed by [CONTACT_103] -validated assay retrospectively . Subjects who are positive for 
somatic pathogenic BRCA [ADDRESS_1044446] results
(blood, saliva, or tissue) must be confirm ed as positive by [CONTACT_456] -
validated assay durin g screening before being able to enter the treatm ent 
phase.
c.Prescreening AEs: AEs and serious AEs related to blood or recent tumor tissue 
collection procedures, as well as death from any cause, will be collected for 
30days after the procedures for subjects who sign the prescreening consent . 
d.Main study informed consent: Only biomarker positive subjects may sign the 
main study informed consent, which Main study consent must be signed prior 
to the conduct of any study -related procedures in the Screening Phase.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
10
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
9.1.2. Prescreening 
Phase for Biomarker 
EvaluationText revised to note that if the subject is biomarker -positive by [CONTACT_456] -validated 
blood -or tissue -based assay, then he is eligible to enter the Screening Phase. Subjects 
who are po sitive for pathogenic BRCA1 or BRCA2 mutations based on local test results 
(som atic or germline) can enter the Screening Phase.
9.1.3. Screening 
PhaseCriteria for screening and advancement to the treatment phase clarified as:
Subjects positive for germli ne pathogenic BRCA [ADDRESS_1044447] results (blood or saliva); 
Subjects positive for somatic pathogenic BRCA1 or BRAC2 mutations (blood, 
saliva, or tissue) based on local results confirmed as positive by [CONTACT_103] -validated assay during screening.
9.7. Biomarkers ;
Table 5Information on biom arker -positivity criteria (ie, genomic lesions required for positivity) 
was removed from text and Table 5, as the definitions for positivity may evolve.
Information on the method of histone deacetylase 2 gene (HDAC2 )detection was also 
removed.
9.7.1. Evaluations New  subsections on tissue analysis and saliva testing were added as shown below :
[IP_ADDRESS]. Tum or tissue (either archival or recently collected) should be obtained to 
evaluate DRD status, and may also be used to identify markers associated with 
disease evolution, immune context, or response to study drugs. Tissue samples 
collected at screening may be used for concordance and bridging studies for the 
development of the assay. Furtherm ore, tumor tissue may be assessed for RNA 
signatures predictive of response to niraparib.
[IP_ADDRESS]. Testing via a saliva sample may be collected to evaluate for germ line 
mutations. Subjects will be permitted to be screened and enter the treatm ent phase 
if positive for BRCA1 or BRCA2 germ line pathogenic mutations.
11.3. Efficacy 
AnalysesThe follow ing text was added:
Anti -tumor activity, such as PSA response, CTC conversion, composite response 
rate, will be analyzed based on subgroups of the enrolled population of biallelic, 
monoallelic, and indeter minant (local test results only) biom arker status. Additional 
details will be provided in the SAP.
11.6. Biomarker 
AnalysesText was updated as follows (deletions appear in overstrike, new text in bold):
The concordance of DNA -repair anomalies in genes between am ongtumor DNA and 
plasma ctDNA results will may be evaluated. Analysis of biallelic loss in comparison to 
monoallelic mutation calling w ill be performed to determine if monoallelic mutation 
calling can be a proxy for biallelic loss.
Rationale: To align guidance on the use of niraparib with selected concomitant medications.
1.2.Summary of 
Available Nonclinical 
and Clinical DataPreclinical information on induction was updated.
8.2. Restricted 
Concomitant 
MedicationsText revised to qualify niraparib as a weak inducer of cytochrom e P450 (CYP )1A2 in 
vitro , and to remove reference to P-glycoprotein (P-gp) inhibitors; further clarification 
was added regarding the concomitant use of niraparib w ith medications that are sensitive 
or moderately sensitive substrates of CYP1A2.
Attachment [ADDRESS_1044448] of CYP1A2 substrates and P -gP
inhibitors removed and replaced w ith links to relevant references.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
11
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Rationale: The noted conditions will be reported as part of the time to symptomatic skeletal events endpoint.
Attachment [ADDRESS_1044449] compression, 
and cauda equine syndrome.
Rationale: Detail regarding specific blood collection tools was removed.
[IP_ADDRESS]. Circulating 
Tumor Cells; 
9.7.1. 3.Whole Blood 
for RNAText describing the type of tube used for blood collection was deleted. 
[IP_ADDRESS]. Circulating 
Tumor DNAMinor edits were made to address the use of plasma samples and assay development .
Rationale: Information added to note where follow -up measures will be documented , and to clarify the local 
regulations regarding contact [CONTACT_762421] w ithdraws consent.
10.2.Withdraw al 
from the StudyText was updated as follows (bold text indicates new text):
The measures taken to follow up must be documented in the subjects’ source 
documents .
If the subject w ithdraws consent for all study -related procedures, then no further contact 
[CONTACT_762422] , except as permitted by [CONTACT_13125] .
Rationale: Minor changes, corrections, and errors w ere addressed throughout the protocol.
17.11. Use of 
Information and 
PublicationMinor changes made as applicable in alignment with current protocol template.
Throughout the 
protocolThe term “patient” was revised to“subject” as appropriate. 
Minor grammatical, formatting, abbreviations, or spelling changes were made.
Amendment 6 (20 June 2019)
The overall reason for the amendment: is to modify and clarify the protocol’s inclusion and exclusion criteria 
to align with current clinical practice for the treatment of patients with metastatic prostate cancer based on 
protocol steering committee feedback and to reflect the characteristics of the third line mCRPC population.  
Applicable Section(s) Description of Change(s)
Rationale: The protocol inclusion and exclusion criteria were revised to reflect the characteristics of the third line 
metastatic castration -resistant prostate cancer (mCRPC) population and to align with current clinical practice.  
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
12
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Synopsis (Overview of 
Study Design and 
Subject Population); 3. 
Study Design; 4. 
Subject Population; 4.2. 
Inclusion Criteria; 
9.1.2. Prescreening 
Phase for Biomarker 
Evaluation Prior to this amendment, potential subjects w ere required to progress on a taxa ne-
based chemotherapy, and AR -targeted therapy, both in mCRPC. In current clinical 
practice, based upon the CHAARTED and STAMPEDE data, taxane -based therapy is 
now given in the metastatic castration -sensitive prostate cancer (mCSPC) setting, such 
that resi stance or intolerance to chemotherapy could have occurred in the mCSPC 
setting and rechallenge in the mCRPC setting would be of no benefit. Lavaud et al. 
observed those patients who received docetaxel rechallenge when they developed 
mCRPC have limited bene fit from this treatment, as assessed by a PSA decline ≥50% 
obtained only in 14% of the patients in first -or second -line treatment.[ADDRESS_1044450] line and the overall benefit -
risk remains unchanged. This change was noted in Inclusion Criterion 5, Synopsis, 
and Sections 3, 4, and 9.1.2.
4.1. Prescreening 
Eligibility Criteria; 
9.1.2. Prescreening 
Phase for Biomarker 
EvaluationPrescreening Criterion 2 was edited to remove ‘if feasible’ as a qualifier for a potential 
subject’s willingness to provide a tumor tissue sample, in order to highlight the 
importance of this sample. This change was also made in Section 9.1.2.
4.2. Inclusion Criteria Inclusion Criterion [ADDRESS_1044451] the units used to report creatinine 
clearance.  
4.3. Exclusion Criteria Exclusion Criterion 15 w as amended to decrease the minimum number of days 
required betw een a transfusion or receipt of he matopoietic grow th factors and Cycle 1 
Day 1 from 30 days to 14 days. No minimum number of days are now required prior 
to Cycle 1 Day 1 for receipt of an investigational agent for prostate cancer or major 
surgery. 
Rationale: Text in the protocol w as upda ted to reflect that a sponsor -validated blood -and tissue -based biomarker 
assay to detect biallelic DNA -repair anomalies is now available.  
Synopsis (Objectives, 
Endpoints/Assessments, 
and Hypothesis); 
Synopsis (Overview of 
Study Design); Time 
and Events Schedule; 
2.1. Objectives and 
Endpoints/Assessments; 
3. Study Design; 9.1.2. 
Prescreening Phase for 
Biomarker Evaluation; 
9.7. Biomarkers; 11.1. 
Analysis PopulationsText in the protocol has been updated to reflect that a sponsor -validated blood -and 
tissue-based biomarker assay to detect biallelic DNA -repair anomalies is now  
available. As a result, the ITT Population is now defined as all subjects with biallelic 
DNA -repair anomalies as determined by a sponsor -validated blood -or tissue -based 
assay.
4.1. Prescreening 
Eligibility CriteriaFor Criterion 2, ‘using a sponsor -validated assay’ was added to describe the method 
needed for determination of DNA -repair anomalies. 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
13
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Rationale: Serial PK sampling assessment on a subset of subjects has been removed from the protocol. The PK 
of niraparib monotherapy has been adequately characterized; therefore, only sparse PK sampling is required for 
this study. 
Synopsis 
(Pharmacokinetic 
Evaluati ons and 
Pharm acokinetics and 
Exposure -Response); 
Time and Events 
Schedule; 9.1.1. 
Overvie w; 9.3.1 Sample 
Collection and 
Handling; 9.3.3. 
Pharm acokinetic 
Parameters; 11.4. 
Pharm acokinetic 
AnalysesText describing serial PK sampling was removed from the prot ocol.
Rationale: Clarification was added that the confirmation scan should occur [ADDRESS_1044452] documentation 
of objective response for soft tissue disease (with the allowance of a 2 -week window ). This schedule is consistent 
with the current protocol attachments that describe RECIST 1.1. 
Time and Events 
Schedule; 9.2.2. 
Endpoints CriteriaThe time of the confirmation scan was clarified to be [ADDRESS_1044453] 
documentation of objective response for soft tissue disease (with the allowance of a 
2-week window ). The schedule for subsequent scans will be based upon Cycle 1 Day 
1, and the confirmation scan will satisfy the scan requirements for the next occurring 
timepoint per the Time and Events Schedule.  
Rationale: Minor changes, corrections, and errors w ereaddressed throughout the protocol.
Synopsis (Overview of 
Study Design); 3. Study 
DesignFor consistency, ‘approximately’ was added before the number of subjects planned to 
be enrolled w ith BRCA1 or BRCA2 DNA- repair anomalies and the number of 
subjects pl anned to be enrolled w ith ATM, FANCA, PALB2, CHEK2, BRIP1, or 
HDAC2 DNA -repair anomalies.
2.1. Objectives and 
Endpoints/AssessmentText for the exploratory endpoint ‘time to unequivocal clinical progression’ was 
edited for accuracy to include the word ‘cl inical’.   
6.2.1. Non -hematologic 
toxicitiesThe title of Table 2 w as edited by [CONTACT_1583] ‘drug -related’ in order to align with the text 
in Section 6.2.1.
9.1.3. Screening Phase Removed that a subject requires sponsor approval and agreement to be rescreened. 
Rescreening is solely at the discretion of the investigator.
9.1.6. Follow -up Phase Clarified that regular imaging should be collected from the EoT visit until 
radiographic progression only for subjects who have not started a subsequent 
treatm ent for prostate cancer or w ithdrawn consent. 
9.7. Biomarkers Table [ADDRESS_1044454] of examples of CYP1A2 substrates, (R)warfarin was changed to warfarin.
Investigator Agreement 
PageThe name [CONTACT_762454], 
MD to Shinta Cheng, MD.
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
14
Approved , Date: 17 July 2020Amendment 5 (30 November 2018)
The overall reason for the amendment: Based on the updated safety information of niraparib w ith more 
subjects exposed to drug and to be consistent with clinical practice of physicians, changes were made to 
inclusion/exclusion criteria and other study -related procedures throughout the protocol .
Applicable Section(s) Description of Change(s)
Rationale:   Changes were made due to anticipated availability of a tissue -based assay.
Synopsis, Objectives, 
Endpoints/Assessments, 
And Hypothesis, 
Overvie w of Study 
Design; Time and 
Events Schedule, 
footnote ‘b’; 9.1.2. 
Prescreening Phase for 
Biomarker Evaluation; 
9.7. BiomarkersThroughout the protocol, the subject enrollment criteria to allow  for enrollment based 
on tissue determination of DNA -repair anomalies once an algorithm that can 
distinguish biallelic from monoallelic DNA -repair anomalies is available w as 
included.
Rationale: The anticoagulation criterion was removed as additional experience with niraparib has not suggested 
increased risk of bleeding if subjects are on anticoagulation agents.
4.3. Exclusion Criteria 
(Criterion 16)Follow ing text was deleted:
Subjects who are currently taking anticoagulation therapy (eg, warfarin, enoxaparin, 
dabigatran, rivaroxaban).
Rationale: Based on the updated safety information of niraparib, QT  interval prolongation w as not identified as 
a risk.
4.3. Exclusion Criteria 
(Criterion 11)Follow ing text was deleted:
Corrected QT interval by [CONTACT_143022] (QTcF) on the screening 
ECG >450 msec.
Rationale: Revision and modificat ions were made for clarity and consistency with the updated safety 
information of niraparib.
Time and Events 
ScheduleTimepoints of assessment of vital signs, blood pressure and physical examination 
were updated and frequency was reduced.
4.1. Prescreening 
Eligibility Criteria, 
Criterion 3Text was updated as follows (bold text indicates new text):
Must have documented evidence of disease progression while beon or after second-
line of treatment for mCRPC.
4.2. Inclusion Criteria
(Criterion 5)Text was updated as follows (bold text indicates new text):
Received at least 1 line of taxane- based chemotherapy for the treatment of mCRPC 
with documented evidence of disease progression prior to enrollm entwhile on 
therapy or w ithin 3 months after discontinuation of therapy in the castrate resistant 
setting .
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
15
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
4.2. Inclusion Criteria
(Criterion 6)Text was updated as follows (bold text indicates new text):
Received at least 1 line of AR-targeted therapy (eg, abiraterone acetate plus 
prednisone, enzalutamide, apalutamide) for mCRPC with documented evidence of 
disease progression prior to enrollm entwhile on therapy or within 3 months after 
discontinuation of therapy in the castrate resistant setting.
4.2. Inclusion Criteria
(Criterion 14)Criteria for certain screening laboratory parameters were updated as follows ( bold 
text indicates new text) :
e.Serum creatinine ≤1.5 x upper limit of normal (ULN), or a calculated c Creatinine 
clearance ≥630 mL/min/1.73 m2using the Cockcroft Gault equation .
fSerum potassium ≥3.5 mmol/L
gSerum total bilirubin ≤1.5 × ULN or direct bilirubin ≤[ADDRESS_1044455] (Note: in subjects 
with Gilbert’s syndrome, if total bilirubin is >1.[ADDRESS_1044456] bilirubin is ≤1.[ADDRESS_1044457] may be eligible)
hAspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
≤3.[ADDRESS_1044458] and ALT ≤[ADDRESS_1044459] in the presence of liver metastases
4.3. Exclusion Criteria 
(Criterion 4)Text w as updated as follows:
Known Symptomatic or impending cord compression, except if subject has received 
definitive treatment for this and demonstrates evidence of clinically stable disease.
4.3. Exclusion Criteria 
(Criterion 5)Text w as updated as follows:
Known Symptomatic uncontrolled brain or leptomeningeal metastases (controlled is
defined as CNS disease which has undergone treatment [eg, radiation or surgery] at 
least 15 days prior to Cycle 1 Day 1)
4.3. Exclusion Criteria 
(Criterion 10)Text w as updated as follows (bold text indicates new text):
Prior palliative radiotherapy ≤715days prior to Cycle 1 Day 1 . Radiotherapy given 
>[ADDRESS_1044460] resolved to Grade 1 or baseline. , with the exception of a single 
fraction of radiot herapy for the purposes of palliation, which is permitted.
4.3. Exclusion Criteria 
(Criterion 17)Text w as updated as follows (bold text indicates new text):
Subjects with uncontrolled (persistent) hypertension Grade ≥3 (ie, Stage 2 
hypertension [systoli c blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 
mm Hg]) confirmed by [CONTACT_762423] [BP] 
≥160 mm Hg or diastolic BP ≥100 mm Hg) despi[INVESTIGATOR_762409] m anagement.
Table 5. Biomarker 
Panel and Criteria for 
Positi vityControl genes (AR, TP53, and CDK2NA) and the footnotes with related cross 
references in table were deleted from the table.
9.2.2. Endpoints Criteria Text for bone scan progression was updated and clarified.
The text on duration of tumor response was updated to make it consistent with the 
secondary objective of study. Text w as updated as follows (bold text indicates new 
text):
The duration of tumor response w ill be assessed from the first time of observed 
CR/PR to the date of radiographic progression (as per PCWG3) , unequivocal clinical 
progression, or death, whichever occurs first .
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
16
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
9.9. Safety (Adverse 
Events)Text w as updated as follows:
Potential AEs will be reported by [CONTACT_423] (or, w hen appropriate, by a caregiver, 
surrogate, or the subject' s legally acceptable representative) for the duration of the 
study and investigators will determine if the events are recorded as AEs . AEs will be 
followed by [CONTACT_23803] 12, Adverse Event Reporting.
10.1. Discontinuation of 
Study TreatmentThe criterion of need for chronic opi[INVESTIGATOR_762410].
The criterion of use of exter nal beam radiation therapy to relieve skeletal 
symptoms under tumor progression was updated to “Radiation therapy”
The criterion of the need for tumor -related orthopedic surgical intervention under 
tumor progression was updated to “Surgical interventions f or com plications due to 
tumor progression”
“Diagnosis of MDS/AML” was newly added under criteria for discontinuation of 
study treatment.
Text w as added indicating that “ Palliative radiation therapy for bone pain m ay 
not require a subject to be discontinued from treatm ent, after discussion with 
the m edical monitor.”
14.4. Preparation, 
Handling, and StorageFollow ing sentence was added: 
“Caregivers should handle niraparib w ith protection (eg, gloves)”
Rationale: Based on the updated safety information of niraparib, the requirements for ECGs have been modified.
Time and Events 
Schedule, including 
Footnote ‘g’ ; 9.9. Safety 
(Electrocardiogram 
[ECG])Specified that triplicate ECGs are not required. A standard 12-lead ECG recording 
will be used in this study.
Footnote ‘g’ was updated as follow s (bold text indicates new text):
Standard 12 -lead ECGs will be performed at screening, at every cycle through 
Cycle 7, at every 3 cycles thereafter, at the EoT visit, andas clinically indicated.
The follow ing text was deleted:
Triplicate ECGs must be performed at approximately the same time of day (±3 hours) 
at each cycle
Rationale: Benefit -risk assessment for niraparib monotherapy was added to supplement the protocol.
1.3. Benefit/Risk 
AssessmentBenefit -Risk Assessment section added.
Rationale: Dose modifications and management of drug toxicities (hematologic and non -hematologic) were 
updated to reflect the clinical practice of physicians.
6.2. Dose Modification 
and Management of 
ToxicityIt was clarified that any re -escalation of the reduced dose to a full starting dose should 
be discussed in advance with Sponsor’s medical monitor.
6.2.1. Non -hematologic 
ToxicitiesText w as updated to clarify the dose modifications in drug -related Grade 3 or higher 
toxicities.
[IP_ADDRESS]. Hepatic 
ToxicitiesSince hepatic toxicities are known potential side effect of niraparib, new  section was 
added to clarify the dose modification criteria for hepatic toxicities. 
New  Table 3. Dose Modification Criteria for AST/ALT/Bilirubin Abnormalities for 
Niraparib added.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
17
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
6.2.2. Hematologic 
ToxicitiesNew  text was added to clarify that the site should contact [CONTACT_762424] 1 or baseline after 28 days of dose interruption or a diagnosis of MDS/AML is 
confirmed by a hematologist.
6.3. Treatment 
Interruptions for 
Planned ProceduresNew  section added to clarify the duration of int erruption of nirparib dose for planned 
procedures that require hospi[INVESTIGATOR_059].
Table 4, Dose 
Modification/Reductions 
for Hematologic 
Toxicity (Platelet Count 
and White Blood Cell 
Count)“White Blood Cell” w as replaced w ith “Neutrophil” in the table heade r.
Rationale: To be consistent with Patient -reported Outcome (PRO) completion guidelines.
Time and Events 
Schedule; 9.1.1. 
Overvie wPatient -reported Outcomes should be performed first prior to any study -related 
procedures if multiple assessments are planned at the same timepoint.
New  footnote “i” was added in Time and Events Schedule.
Rationale:   Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
Amendment 4 (20 March 2018)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The prim ary reason for the amendment: is to improve the subject selection criteria based on using an 
enhanced biomarker assay and the corresponding statistical analysis plan, to remove Holter monitoring, and other 
minor changes throughout the protocol.
The rationale for and description of the changes are listed below , and representative revisions are sometimes 
provided; when revisions are provided verbatim, bold font denotes ne w text and strikethrough denotes deleted 
text.
Applicable Section(s) Description of Change(s)
Rationale: Internal sponsor analyses on subjects enrolled in this study prior to [ADDRESS_1044461] greater clinical benefit from treatment with niraparib. Therefore, the primary endpoint analysis 
of the study was amended to evaluate the response of these subjects. A secondary endpoint analysis to evaluate 
the response of subjects with other DNA -repair anomalies (in ATM, FANCA, PALB2, CHEK2, BRIP1, or 
HDAC2 ) was added. In addition, a futility analysis for subjects with measurable mCRPC who have biallelic 
DNA -repair anomalies in ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2 was implemented to ensure that 
recruitment of these subjects is not continued if an adequate response is not initially observed.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
18
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Synopsis (Objectives, 
Endpoints/Assessments, 
and Hypothesis);
Synopsis (Overview of 
Study Design);
2.1. Objectives and 
Endpoints/Assessments;
3. Study DesignUpdates w ere m ade to the patient population, the number of subjects enrolled in 
each population, and to the primary and secondary objectives and endpoints of the 
study.
Table 4 Revisions and clarifications were made to the table and footnotes, and a new 
footnote was added.
Synopsis (Statistical 
Methods );
11.2. Sample Size 
DeterminationDescriptions of primary and secondary objectives with objective response rate 
(ORR) endpoint were revised based on updates to the patient population. In addition 
to the interim efficacy analysis for the primary endpoint (as in the original protocol),
a futility analysis for ORR based on Simon’s tw o-stage design was added for the 
secondary objective in subjects with measurable mCRPC who have biallelic DNA -
repair anomalies in ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2.
11.1. Analysis Population ITT Population: All subjects who have biallelic DNA -repair gene anomalies (as 
determined by [CONTACT_456]’s required blood -based assay) and were enrolled after 
07Decem ber 2017 . This population will be used for efficacy analyses.
11.3. Efficacy Analyses The primary endpoint, ORR in subjects with measurable mCRPC and 
DNA -repair anom alies in BRCA1 or BRCA2 and ORR in subjects with 
measurable mCRPC and DNA- repair anom alies in ATM, FANCA, PALB2, 
CHEK2, BRIP1, or HDAC2 , as defined in Section 2.1, w ill be calculated, and its 
2-sided 95% exact CI will also be presented.
The final analysis for ORR in subjects with measurable mCRPC and 
DNA -repair anom alies in BRCA1 or BRCA2 will be performed approximately 
6months after the last subject with meas urable disease and DNA -repair anom alies 
in BRCA1 or BRCA2 receives his first dose of study medication.
Rationale: Two more study visits were added to Cycle 1, to enhance safety monitoring.
Time and Events 
ScheduleTwo columns were added to Cycle 1 (for Day 8 and Day 22 timepoints), to provide 
weekly monitoring during the first cycle.
Rationale: The requirement for Holter monitoring was removed, since triplicate ECGs are required on Day 1 of 
every cycle, and no concern for QT prolongation has been observ ed in other studies.
Synopsis 
(Pharmacokinetic 
Evaluations);
Time and Events 
Schedule, including 
Footnotes g and k;
9.3.1. Sample Collection 
and Handling;
9.9. Safety 
(Electrocardiogram 
[ECG])The requirement for Holter monitoring was removed.
Specified that triplicate ECGs are required.
Rationale: Revisions and modifications were made throughout the protocol to increase clarity and consistency, to 
update the protocol based on revisions made during this amendment, or to correct omissions and errors.
Throughout the protocol Minor grammatical, formatting, or spelling changes were made. 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
19
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Throughout the protocol “3 months” was revised to “12 weeks” (or “12 w eeks” was added in parenthesis 
after “3 months”), “6 months” w as revised to “24 weeks”, “sponsor’s blood -based 
assay” was revised to “sponsor’s required blood -based assay”.
Time and Events 
Schedule;
9.1.3. Screening PhaseThe Screening Phase was reduced from 35 days to 28 days in order to allow  subjects 
to receive the Cycle 1 Day 1 dose sooner.
Abbre viations Abbreviations and definitions were added.
4.1. Prescreening 
Eligibility CriteriaCriterion 4 was deleted. Details will be provided in the laboratory manual.
4.2. Inclusion Criteria 
(Criterion 8)a.PSA progression defined by a minimum of 2 rising PSA levels with an interval 
of ≥1 w eek between each determination (per Prostate Cancer Working Group 3 
[PCWG3] criteria).19The PSA level at the screening visit should be ≥2 1μg/L 
(21ng/mL).
4.2. Inclusion Criteria 
(Criterion 14)h.Aspartate aminotransferase (AST) or andalanine aminotransferase (ALT) 
≤3.[ADDRESS_1044462] and ALT ≤[ADDRESS_1044463] in the presence of liver metastases
i.CTC count of ≥1 cells/7.5 mL blood (required only for patients with 
non-measurable soft tissue disease by [CONTACT_393] 1.1)
6.2. Dose Modification 
and Management of 
ToxicityFor procedures while on treatment, dose interruption of up to [ADDRESS_1044464] be discussed in advance with the 
sponsor’s medical monitor.
6.2.1. Non -hematologic 
ToxicitiesThis section was revised for accuracy, and repetitions were removed.
6.2.2. Hematologic 
ToxicitiesRepetitions were removed based on text added to Section 6.2. Management of 
anemia was amended to align with institutional standards of care.
The order of dose reductions for Grade ≥[ADDRESS_1044465] dose, and a note w as modified as shown below.
Weekly monitoring and/or interruption are not required if at baseline grade, eg, 
subject w ith baseline Hgb 9.1 (grade 2 anemia) does not need to be monitored 
weekly for grade [ADDRESS_1044466]’s subject is on a second- line of therapy 
provided the subject is demonstrating signs of progression (eg, rising PSA or 
radiographic progression) .
If no tumor tissue is available, then the subject may agree be asked to have a new 
tumor tissue sample collected , if reasonable .
For consistency for changes in Section 4.1, the following sentence was deleted: 
“Subjects may be rescreened once for biomarker -positivity during the Prescreening 
Phase for the reasons described in Section 4.1, Criterion 4.”
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
20
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
9.7. Biomarkers To be eligible for the study, subjects must be confirmed biomarker -positive by [CONTACT_103]’s required blood -based assay. To ensure that all su bjects have the same 
biomarker data available for analysis ( ieeg, for concordance and bridging studies), 
blood samples will be collected and analyzed from all subjects who sign the 
prescreening ICF. Tissue samples will also be collected for additional bio marker 
research.
Clarifications and revisions were made to Table [ADDRESS_1044467] may withdraw  consent for use of samples for future research (refer to 
Section 16.2.5, Long -Term  Retention of Samples for Additional Future Research).
11.11. Safety Analyses 
(Clinical Laboratory 
Tests)Clinical laboratory test results will be collected from screening through [ADDRESS_1044468] dose of study drug the EoT visit .
12.3.4. Disease 
Progression and DeathFatal events (regardless of relationship to study drug) should be reported as SAEs 
for subjects until [ADDRESS_1044469] dose of study drug should include an AE term 
for the cause of death (if k nown). Fatal events occurring after that [ADDRESS_1044470] information about his survival status.
References A new reference was added. The edition number and year were deleted from the 
citation f or the Investigator’s Brochure.
Amendment 3 (4 October 2017)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The prim ary reason for the amendment: is to include additional cardiac monitoring to better understand the 
cardiovascular effect of niraparib monotherapy in the prostate cancer population. This additional safety 
monitoring is precautionary only and is not indi cative of a known cardiac signal for niraparib. An ITT Population 
was also added to allow  for all subjects with biallelic DNA -repair anomalies to be analyzed separately for 
efficacy. Other minor changes (ie, removal of pharmacodynamics sampling and updates to the 
inclusion/exclusion criteria) are also included in this amendment.
Applicable Section(s) Description of Change(s)
Rationale: Additional 12 -lead electrocardiogram (ECG) Holter monitoring (24 hours) was added for subjects 
who are undergoing serial PK sampling for analysis of QT/QTc in relation to plasma concentrations of niraparib 
and M1.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
21
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Synopsis; Time and 
Events Schedule; 9.9.
Safety 12-lead ECG Holter monitoring was added for subjects who are selected for serial 
PK sampling.
9.3.1. Sample Collection 
and HandlingA reference to Holter monitoring for subjects who undergo serial PK sampling was 
added.
Rationale: Subjects w ith biallelic DNA -repair anomalies are expected to have better clinical response outcomes 
than those subjects with monoallelic DNA -repair anomalies. Therefore, the sponsor intends to analyze these 
subjects separately for efficacy. To that end, a n ITT Population comprising subjects who have biallelic 
DNA -repair gene anomalies (as determined by [CONTACT_456]’s blood -based assay) was added.
11.1. Analysis 
PopulationsThe Treated Population was amended to Enrolled Population to allow  for all 
subjects enrolled in the study to be analyzed. An ITT Population was added to allow  
for all subjects with biallelic DNA -repair anomalies to be analyzed separately for 
efficacy.
Rationale: Pharmacodynamics sampling (ie, whole blood for isolation of PBMCs) was remov ed from the 
protocol. All blood samples collected to date are unusable due to contamination with high levels of poly-
adenosine diphosphate [ADP] -ribose (PAR) , likely from red blood cell lysis. Furthermore, preliminary data 
suggest that >50% of this subject population w ould y ield PBMC counts below  the threshold needed to exceed the 
PAR lower limit of detection.
Synopsis: 
Pharm acody namic 
Evaluations; Time and 
Events Schedule; 9.1.1. 
Overvie w; 9.1.4. 
Treatment Phase; 9.5. 
Pharm acody namics; 9.6. 
Pharm acokinetic/ 
Pharm acody namic 
Evaluations; 11.5 
Pharm acody namic 
Analyses; 11.8. 
Pharm acokinetic/ 
Pharm acody namic 
AnalysesPharm acody namics sampling and analyses were removed.
2.1. Objectives and 
Endpoints/AssessmentsThe exploratory endpoint to quantif y PAR levels in PBMCs w as removed.
Rationale: Minor amendments
Time and Events 
Schedule; 9.1.4. 
Treatment Phase; 9.1.5. 
End-of-Treatm ent Visit; 
12.3.4; Disease 
Progression and DeathThe definition of End -of-Treatment visit was amended to clarify that the visit 
should occur 30 (±5) days after the last dose of study drug or 30 (±5) days after the 
end of study drug interruption period.
Time and Events 
ScheduleThe footnote for blood pressure monitoring was removed. Blood pressure will be 
measured at every cycle until the End -of-Treatment visit; no cap on the number of 
cycles will be implemented.
Synopsis; Time and 
Events Schedule; 9.2.1. 
Evaluations; 9.2.2. 
Endpoints CriteriaThe instructions regarding tumor measurements and collection of imaging scans 
wasupdated to clarify different procedures for soft tissue response versus bone scan 
progression. Reference to the protocol body for additional details was added in the 
Time and Events Schedule footnote.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
22
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Synopsis; 2.1. Objectives 
and 
Endpoints/AssessmentsClarified that the endpoint for CTC response should be performed for subjects who 
have baseline CTC >0.
Synopsis; 3. Study 
Design; 4. Subject 
PopulationClarified that subjects should have progressed on or after at least [ADDRESS_1044471] 1 line of AR -targeted therapy (eg, abiraterone 
acetate plus prednisone, enzalutamide, apalutamide).
4.1. Prescreening 
Eligibility CriteriaCriterion 2 w as updated to state that tumor tissue samples should be collected “if 
feasible”. This is to allow subjects who may not be able to provide a tumor tissue 
sample to enter the study if a blood sample is available.
Criterion [ADDRESS_1044472] documented evidence of disease 
progression while on second -line of therapy.
Crite rion 4 w as updated to clarify when subjects could be rescreened for biomarker -
positivity.
4.2. Inclusion Criteria Minor amendments were made to inclusion criteria 5 and 6 to clarify the timing of 
discontinuation for prior taxane -based chemotherapi[INVESTIGATOR_762411] -targeted therapi[INVESTIGATOR_014]. 
Criterion 7 w as updated to remove the requirement for tumor tissue to be 
biomarker -positive, given that subjects may be biomarker -positive based on the 
blood -based assay.
4.3 Exclusion Criteria Criterion 12 w as deleted. Medications thought to cause QT prolongation were 
instead added to Section 8.2 Restricted Concomitant Medications.
Criterion 16 w as added to exclude subjects who are taking anticoagulation therapy.
Criterion 17 w as added to exclude subjects with uncontrolled Grad e ≥[ADDRESS_1044473] and to allow  for treatment interruption of Grade 1 and 2 non -
hematologic toxicities at the discretion of the investigator. Clarified that treatment -
related toxicities of Grade 3 or 4 require a dose reduction.
6.2.2. Hematologic 
ToxicitiesInstructions for dose modifications/reductions for hematologic toxicities were 
updated to reflect toxicity grades, rather than spec ific laboratory values. 
6.3. Cycle 1 Day 1 and 
Treatment Continuation 
CriteriaNew  section added to provide criteria for allow ing subjects to be retreated with 
study drug.
8.1. Prohibited 
Concomitant 
Medications; 8.2. 
Restricted Concomitant 
MedicationsMedications thought to cause QT prolongation or torsades de pointes were changed 
from prohibited to restricted medications. 
9.1.2. Prescreening Phase 
for Biomarker EvaluationModified to allow  for subjects who may not be able to provide a tumor tissue 
sample.
9.2.1. Evaluations; Information regarding collection of scans to determine objective response and 
radiographic progression was moved to Section 9.2.2. 
9.2.2. Endpoints Criteria Information regarding collection of scans to determine objective resp onse and 
radiographic progression was added to this section. 
9.7. Biomarkers The requirement to have biomarker -positivity determined by [CONTACT_762425].
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
23
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
The positivity criteria for the biomarker assay was updated to reflect the current 
blood -based assay.
10.1. Discontinuation of 
Study TreatmentUpdated to remove discontinuation due to drug -induced liver injury, as the 
information conflicted with toxicity management guidance provided in Section 6.
Updated QTc discontinuation criteria t o state “clinically significant QTcF >500 
msec or QTc prolongation >60 ms above baseline ”
11.[ADDRESS_1044474] of anticipated events to be disease -specific.
Rationale: Minor errors w ere noted and corrected
Throughout the protocol Minor grammatical, formatting, or spelling changes were made. 
Amendment 2 (25 January 2017)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: The overall reason for the amendment is to address feedback from a 
Type C Meeting with FDA held on 19 October 2016, as w ell as feedback from other health authorities.
Applicable Section(s) Description of Change(s)
Rationale: The primary endpoint of the study was amended to comply with feedback from health authorities. The 
primary endpoint was changed from a composite endpoint to objective response rate (ORR). With this change, 
the subject population for the primary analysis w ill include only subjects with measurable disease. Subjects with 
non-measurable disease will still be included in the study to increase the size of the safety database and assess the 
activity of niraparib in this population.
Synopsis; 2.1. 
Objectives and 
Endpoints/AssessmentsThe primary endpoint is changed from a composite endpoint to an endpoint of 
objective response rate (ORR) in subjects w ith measurable disease.
Given that circulating tumor cell (CTC) response was no longer included in the 
primary en dpoint, an additional secondary endpoint to measure CTC response was 
added. The exploratory endpoint to evaluate CTC counts was also updated based on the 
new secondary endpoint.
The original composite primary endpoint was changed to be an exploratory endpoint.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
24
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
An additional exploratory endpoint of time to unequivocal progression was included.
Synopsis; 2.2. 
HypothesisThe hypothesis was amended to reflect the ne w primary endpoint and corresponding 
statistical assumptions.
Synopsis; 3. Study 
DesignThe study design was updated to amend the number of subjects to be included in the 
study, and to be aligned with Section 11.2 Sample Size Determination. Other 
administrative changes were made.
Synopsis; Time and 
Events Schedule; 9.1.4. 
Treatment Phase; 
9.2.1. EvaluationsThe new  prim ary endpoint of ORR requires confirmation of response; therefore, details 
of collection and revie w of imaging scans were updated and the time window  for 
collection was changed from ±7 days to ±3 days.
Synopsis; 11.2. Sample 
Size DeterminationThe sample size calculations were amended to reflect the new  prim ary endpoint of 
ORR. Sample size justification for subjects w ith non -measurable disease based on CTC 
RR was also added.
Synopsis; 11.[ADDRESS_1044475] the new primary endpoint of ORR. In 
addition, analysis of CTC RR was added to address the additional secondary endpoint 
of CTC response.
Rationale: To comply with US FDA recommendations
Time and Events 
ScheduleSafety testing at Cycle 2 Day 15 w as added to ensure the safety of subjects early in the 
study, as recommended by [CONTACT_124756].
Rationale: To collect additional PK samples to characterize exposure of niraparib and its metabolite M1.
Synopsis; Time and 
Events Schedule; 9.3. 
Pharm acokinetics; 
11.4. Pharmacokinetic 
AnalysesAdditional serial PK samples were added in a subset of subjects at selected sites. 
Clarification was added that sparse PK sampling will be collected in all subjects.
9.1.1. Overview The maximum volume of bl ood drawn at any visit was amended from 70 mL to 80 mL 
based on the additional PK collections required in a subset of subjects.
2.1. Objectives and 
Endpoints/AssessmentsAdditional exploratory endpoints were included to evaluate the steady -state PK of 
niraparib and its metabolite M1 in a subset of subjects.
Rationale: To clarify the subject population to be included in the study based on health authority and investigator 
feedback
4.1. Prescreening 
Eligibility CriteriaCriterion [ADDRESS_1044476] progressed on their second -line of therapy.
Criterion 4 w as added to allow subjects who are biom arker -negative to be rescreened 
once, to determine if their tumor tissue was insufficient for analysis or to determine of 
their biomarker status changed over the course of their disease.
4.2. Inclusion Criteria Criterion 4 w as updated to clarify that prostate cancer of mixed histology is acceptable; 
however, subjects w ith the small cell pure phenotype of prostate cancer must be 
excluded from the study.
Criterion [ADDRESS_1044477] documented evidence of 
disease progression on previous AR -targeted therapy.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
25
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Criterion [ADDRESS_1044478] 
1.1 (for soft tissue) or PCWG3 (for bone disease) criteria. Clear definitions of 
measurable and non -measurable disease were added. 
Criterion 14 w as updated to amend plate let counts and serum albumin levels at 
screening. In addition, a criterion for CTC count was added (criterion 14.1.i) to define 
the permitted levels at screening.
4.3. Exclusion Criteria Criterion 2 w as updated to clarify that previous chemotherapy should only be an 
exclusion criterion if it was used for the treatment of prostate cancer.
Criterion 11 w as corrected to exclude subjects with QTcF on the screening ECG 
>450 msec, as per ICH E14: The Clinical Evaluation of QT/QTc Interval prolongation 
and Proa rrhythmic Potential for Non -Antiarrhythmic Drugs.
Criterion 15 w as am ended to remove zoledronic acid and denosumab as prohibited 
prior therapi[INVESTIGATOR_014].
Rationale: To ensure consistency with Investigator’s Brochure
Time and Events 
ScheduleAdditional blood pressure measurements were added; blood pressure should now be 
measured at all study visits.
6.2.1. Non -
hematologic toxicitiesThe time permitted for dose interruption was amended from [ADDRESS_1044479] the Investigator’s Brochure and to align with treatment cycles.
6.2.2. Hematologic 
ToxicitiesRecommendations for dose modification/reductions for hematologic toxicity were 
updated to reflect the current Investigator’s Brochure (version 6.0). Updates are 
captured in Table [ADDRESS_1044480] the Investigator’s Brochure and to align with treatment cycles.
9.9. Safety Additional serum chemistry tests have been added and albumin will now  be measured 
at all visits requ iring laboratory testing (not just at screening). These new clinical 
laboratory tests were not added due to any new safety signals and are compliant with 
recommendations in Investigator Brochure version 5.
Attachment 6: 
Anticipated EventsAdditional anticipated events were included to align with the Investigator’s Brochure.
Rationale: To comply with feedback from US FDA regarding the evaluable biomarker population for efficacy 
and to simplify instructions for investigators.
9.1.2. Prescreening 
Phase for Biom arker 
EvaluationAll subjects in the study are required to have tumor tissue and a blood sample collected 
for analysis of biomarkers. Details of how those samples will be analyzed and which 
assays will be used were condensed and were moved to Section 9 .7 Biomarkers. 
New  text was added to clarify that potential subjects can enter the Prescreening Phase 
if they are on second -line therapy.
Rationale: To clarify that imaging scans may be collected during follow -up from subjects who discontinue 
treatment for reasons other than radiographic progression.
Time and Events 
Schedule; 9.1.6. 
Follow -up PhaseThe sponsor intends to collect imaging scans from subjects who discontinue treatment 
for reasons other than radiographic progression, in order to d etermine radiographic 
progression -free survival, provided the subject does not w ithdraw  consent for 
collection of images. Therefore, collection of imaging scans during the Follow -up 
Phase w as clarified, including the collection window  to be applied (ie, ev ery 3 months 
±2 w eeks).
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
26
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Rationale: To clarify withdrawal from study categories and the testing procedures permitted based on the type of 
withdrawal.
10.1. Discontinuation 
of Study TreatmentAdditional categories for w ithdraw al from the study treatment were included and the 
procedures permitted for each category of withdrawal were clarified.
10.2. Withdraw al from 
the StudyClarification was added for follow -up visits to allow  for telephone or chart review. 
Clarification was also added regarding subjects who w ithdraw consent for all study -
related procedures; these subjects must not be contact[CONTACT_762426].
Rationale: Minor amendments
Title Page The study name “Galahad” was added.
Time and Events 
ScheduleClarifications were added regarding the collection window  for follow -up visits, the 
collection of related serious adverse events, the collection of symptomatic skeletal 
events, and the collection of patient -reported outcomes. Collection and review of 
imaging scans was also up dated.
In order to clarify when assessments occur after Cycle 7 (ie, from Cycle 8 onwards), an 
additional column was added for assessments that occur on every cycle. As a result, 
footnotes stipulating that study drug dispensation and treatment compliance are to be 
completed every cycle were deleted.
Time and Events 
Schedule; 9.[ADDRESS_1044481] sites only, and for collection 
PBMCs to be discontinued at the sponsor’s discretion, based on the data collected.
6.1. Study Drug 
AdministrationClarified that missed doses do not cause cycles to be delayed or restarted.
11.10. Interim 
Analysis; 16.1. Study -
specific Design 
ConsiderationsText describing a preliminary assessment of safety and efficacy in the first [ADDRESS_1044482] is not possible because this study will not enroll subjects who cannot give pri or 
informed consent.
Attachment 2: 
Summary of RECIST 
Criteria Version 1.[ADDRESS_1044483] overall response based on PCWG3 criteria.
Attachment 4: 
Prohibited Medications 
That Could Poten tially 
Cause QT Prolongation 
or Torsades de PointesClarified that the table provided is not a complete list and that new medications may be 
considered as appropriate.
Investigator 
AgreementUpdated the sponsor’s responsible Medical Officer.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
27
Approved , Date: 17 July 2020Applicable Section(s) Description of Change(s)
Rationale: Minor errors w ere noted and corrected
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made. 
Amendment 1 (7 July 2016)
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: The overall reason for the amendment is to address feedback from 
FDA received 5 July 2016.
Applicable Section(s) Description of Change(s)
Rationale: ECG monitoring at every cycle was added due to FDA concern regarding higher ECG abnormalities 
in the elderly population.
Time and Events 
ScheduleECG monitoring was added at every cycle.
9.9. Safety 
EvaluationsECG monitoring procedures were clarified.
Rationale: FDA recommendation that toxicities which have not resolved within 21 days should undergo dose 
reduction or discontinuation.
6.2.1. Non -
hematologic 
ToxicitiesToxicities leading to dose modification should be resolved within 21 days, instead of 28 
days.
Rationale: FDA recommendation that a hematologist must be consulted in the event of >[ADDRESS_1044484] was changed to a requirement in 
cases of hematologic toxicity that required >1 transfusion or that did not recover to 
Grade 1 or less after 28 days. 
Rationale: FoundationOne®is the trademarked name [CONTACT_762455] -approved test.
9.1.2. Prescreening 
PhaseThe FoundationOne®gene panel name [CONTACT_44001].
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
28
Approved , Date: 17 July 2020SYNOPSIS 
A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration -Resistant 
Prostate Cancer and DNA -Repair Anomalies
Niraparib is an orally available, highly selective poly (adenosine diphosphate [ADP] -ribose) polymerase 
(PARP) inhibitor, with activity against PARP -1 and PARP -2 deoxyribonucleic acid (DNA) -repair 
polymerases. Niraparib is being investigated for the treatm ent of ovarian, breast, and prostate tumors in 
subjects with DNA -repair anomalies.
OBJECTIVES, ENDPOINTS/ASSESSMENTS, AND HYPOTHESIS
Efficacy objectives will be evaluated for subjects who have either biallelic DNA -repair anomalies (BRCA 
or non-BRCA) as determined by a sponsor -validated blood -or tissue -based assay or germline pathogenic 
BRCA ( BRCA1 or BRCA2 )mutation .
Objectives Endpoints/Assessments
Primary
 To assess the efficacy of niraparib in subjects 
with measurable mCRPC and who have either 
biallelic DNA -repair anomalies in BRCA 
(BRCA1 or BRCA2 )or germline BRCA Objective response rate (ORR) of soft tissue (visceral or nodal 
disease) as defined by [CONTACT_119549] (RECIST) 1.1 with no evidence ofbone progression 
according to the PCWG3 criteria
Secondary
 To assess the efficacy of niraparib in subjects 
with measurable mCRPC and DNA -repair 
anomalies in biallelic non-BRCA (ATM, 
FANCA, PALB2, CHEK2, BRIP1, or 
HDAC2 ) Objective response rate of soft tissue (visceral or nodal disease) 
as defined by [CONTACT_393] 1.1 with no evidence of bone progression 
according to the PCWG3 criteria
 To assess the efficacy of niraparib in subjects 
with mCRPC and DNA -repair anomalies Circulating tumor cell (CTC) response defin ed as CTC=[ADDRESS_1044485] -baseline in subjects with baseline 
CTC >0
 To evaluate response outcomes of niraparib in 
subjects with mCRPC and DNA -repair 
anomalies OS: time from enrollment to death from any cause
 As defined by [CONTACT_43877]3:
 rPFS: time from enrollment to radiographic progression or 
death from any cause, whichever occurs first
 Time to radiographic progression
 Time to PSA progression 
 Time to symptomatic skeletal event (SSE)
 To evaluate the safety and tolerability of 
niraparib Incidence of adverse events
 Clinical laboratory test results
 To evaluate duration of tumor response  Duration of objective response: time from complete response 
(CR) or partial response (PR) to radiographic progression of 
disease, unequivocal clinical progression, or death, whichever 
occurs first
Abbreviations: ATM=Ataxia Telangiectasia Mutated gene; BRCA1=Breast Cancer gene 1; BRCA2=Breast Cancer gene 2; 
BRIP1=BRCA1 Interacting Protein C -terminal Helicase 1 gene; CHEK2=Checkpoint Kinase 2 gene; CR=complet e 
response; CTC=circulating tumor cell; DNA=deoxyribonucleic acid; FANCA=Fanconi Anemia Complementation 
Group A gene; HDAC2=Histone Deacetylase 2 gene; mCRPC=metastatic castration -resistant prostate cancer; 
ORR=objective response rate; OS=overall survival; PALB2=Partner and Localizer of BRCA2 gene; PCWG3=Prostate 
Cancer Working Group 3; PR=partial response; PSA=prostate specific antigen; RECIST=Response Evaluation Criteria 
in Solid Tumors; rPFS=radiographic progression -free survival; SSE=symptomatic skeleta l event
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
29
Approved , Date: 17 July 2020Hypothesis
Niraparib will demonstrate a >15% ORR in subjects with mCRPC and DNA -repair anomalies who have 
measurable disease.
OVERVIEW OF STUDY DESIGN
This is a Phase 2, multicenter, open -label study to assess the efficacy and safety of once daily dosing of 
300mg niraparib in male subjects over the age of [ADDRESS_1044486] received prior taxane -based chemotherapy and AR-targeted therapy .
The study will assess up toapproximately 120subjects with measurable disease who are either biallelic 
BRCA/non -BRCA  according to a sponsor -validated blood -or tissue -based assay or who have a germline 
pathogenic BRCA mutation (approximately 75 subjects with DNA -repair anomalies in BRCA  [BRCA1 or 
BRCA2 ]and approximately 45subjects with DNA- repair anomalies in non-BRCA [ATM, FANCA, 
PALB2, CHEK2, BRIP1, or HDAC2 ]). In addition, at least 90 subjects with non-measurable disease (ie, 
bone disease only) regardless of their DNA  anomaly (ie, BRCA  or non-BRCA) will be included to evaluate 
the activity of niraparib in this population. Efficacy objectives will be evaluated on subjects who have either 
biallelic DNA- repair anomalies as determined by a sponsor -validated blood -or tissue -based assay or 
germline pathogenic BRCA (BRCA1 or BRCA2 )mutation . All subjects will be monitored for safety during 
the study period, and up to [ADDRESS_1044487] of 5 phases; a Prescreening Phase, a Screening Phase, a Treatment Phase, a Follow -
up Phase , and a Long -term Extension Phase .
SUBJECT POPULATION
Male subjects over the age of [ADDRESS_1044488] received prior 
taxane -based chemotherapy and AR-targeted therapy are eligible for the study .
DOSAGE AND ADMINISTRATION
The study drug, niraparib 300 mg, will be provided as capsules (3 x 100 mg) for once daily oral 
administration. The capsules must be swallowed whole. Subjects should take their dose in the morning 
(with or without food) .
EFFICACY EVALUATIONS
The efficacy e valuations include the following:
 Tumor measurements: 
 Chest, abdomen, and pelvis computed tomography (CT) or magnetic resonance imaging (MRI) 
scans and whole body bone scans (99mTc). Imaging will be assessed by [CONTACT_762427] u sed for the primary endpoint analyses. Scans will also be collected and stored by 
a central vendor for central review if indicated. 
 serum PSA  survival status 
 CTC  SSEs
PHARMACOKINETIC EVALUATIONS
Sparse PK sampling will be collected from all subjects in this study. Blood samples to measure plasma 
levels of niraparib and its metabolite, M1, will be obtained on Cycle 1 Day 1 and Cycle 2 Day 1 at predose, 
and between 1 to 3 hours and between 4 to 6 hours postdose. 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
30
Approved , Date: 17 July 2020PATIENT -REPORTED OUTCOMES EVALUATIONS
PROs will be measured as per the Time and Events Schedule utilizing paper versions of the Brief Pain 
Inventory -Short Form questionnaire (BPI -SF), the Functional Assessment of Cancer Therapy -Prostate 
questionnaire (FACT -P), and the Euro- QoL questionnaire (EQ -5D-5L).
BIOMARKER EVALUATIONS
Biomarker evaluations will be conducted as specified in the Time and Events Schedule. CTCs will be 
evaluated for response to study drug. Whole blood for RNA may be used to evaluate potential mechanisms 
of resistance that may be observed following treatment with niraparib. Circulating tumor DNA (ctDNA) 
may be used to screen for changes in the levels or types of DNA -repair anomalies observed over time, to 
monitor for potent ial markers of resistance to niraparib, and for concordance and bridging studies with 
tumor tissue.
SAFETY EVALUATIONS
Safety assessments will be based on medical review of AE reports and the results of vital sign 
measurements, ECGs, physical examinations, clinical laboratory tests, ECOG PS, and other safety 
evaluations at specified timepoints as described in the Time and Events Schedule.
STATISTICAL METHODS
For the primary objective with ORR endpoint in subjects with measurable mCRPC and DNA -repair 
anomali es in BRCA1 or BRCA2, the null hypothesis that the ORR is ≤15% will be tested against the 
alternate hypothesis that the ORR is ≥32%. Efficacy of niraparib will be declared if the lower bound of the 
2-sided 95% Confidence Interval (CI) for ORR is >15%. With approximately 75subjects with measurable 
disease and DNA -repair anomalies in BRCA (BRCA1 or BRCA2 ), the study will have over 90% power 
such that the lower limit of the 95% CI for ORR exceeds 16%. Assuming an enrollment duration of 
approximately 24months, it is anticipated that the final analysis for ORR will occur at approximately 
30months (approximately [ADDRESS_1044489] enrolled).
For the secondary objective with ORR endpoint in subjects with measurable mCRPC and DNA -repair 
anomalies in biallelic non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2 ), the null 
hypothesis that the ORR is ≤15% will be tested against the alternate hypothesis that the ORR is ≥32%. With 
a 1-sided of 0.05 and power of 80%, up to 45subjects with measurable mCRPC and DNA- repair 
anomalies in biallelic non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2 )are to be enrolled 
based on Simon’s two-stage design. At end of Stage 1, approximately 14subjects will be evaluated for
ORR after at least [ADDRESS_1044490] stage. Otherwise, enrollment may 
proceed to the second stage with a total of 45subjects combined for the 2 stages, and the null hypothesis 
will be rejected if 1 0or more responses are observed.
Assuming the historical CTC response rate (CTC RR) of 20% (based on unpublished data from Study COU -
AA-301) and the target CT C RR of 40%, at least 60 subj ects with non -measurable disease will be required 
to provide a lower bound of the 2- sided 95% CI greater than 20%, with a probability of 0.9.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
31
Approved , Date: 17 July 2020Efficacy Analyses
The primary endpoint, ORR, will be calculated, and its 2-sided 95% exact CI will also be presented. The 
final analysis for ORR will be performed approximately [ADDRESS_1044491] dose of study medication.
Pharmacokinetics and Exposure -Response
A population PK analysis of plasma concentration -time data of niraparib will be performed using nonlinear 
mixed -effects modeling to estimate oral clearance (CL/F) and oral volume of distribution (V/F). Other P K 
parameters may be evaluated as appropriate.  
Safety Analyses
Subje cts who receive at least 1 dose of study drug will be analyzed for safety. The safety parameters to be 
evaluated are the incidence, intensity, and type of AEs, vital signs measurements, ECGs, physical 
examination (abnormalities will be recorded as AEs) , and clinical laboratory results.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
34
Approved , Date: 17 July 2020cPrescreening AEs: AEs and serious AEs related to blood or recent tumor tissue collection procedures, as w ell as death from any cause, will be collected for 
30days after the procedures for subjects w ho sign the prescr eening consent.
dMain study inform ed consent : Main study consent must be signed prior to the conduct of any study -related procedures in the Screening Phase.
eMedical History : Medical history obtained during the Prescre ening Phase will be disease -specific on ly.
fWhole blood for cytogenetics : A blood sample collected at screening will be stored for evaluation if the sponsor's medical monitor finds evaluation necessary for 
assessing niraparib -related risk for MDS/AML (eg, the subject develops MDS/AML). The scree ning mutation profile will be analyzed to determine whether any 
mutations were present prior to study treatment. Details on sample collection and analysis are in the laboratory manual.
gECGs : Standard 12 -lead ECGs will be performed at screening, at every cycle through Cycle 7, at every 3 cycles thereafter, at the EoT visit, and as clinically 
indicated (see Section 9.9for details of ECG collection). Any known electrolyte imbalance should be treated prior to performing the ECG.
hCT or MRI; Bone scan : Chest, abdomen, and pelvis CT or MRI scans and whole body bone scans (99mTc) must be evalu ated at screening. Scans performed 
≤8weeks prior to Cycle [ADDRESS_1044492] imaging performed within ±[ADDRESS_1044493] 
documentation of objective response for soft tissue disease, repeat imaging is required 4 weeks later (+ 2 weeks) for confirmation per RECIST 1.1. Details for the 
timing of subsequent scans are provided in Section 9.2.[ADDRESS_1044494] or MRI and bone scans performed ≤6 w eeks prior to the EoT visit may serve as EoT scans.
iPRO Questionnaires : If mul tiple assessments are scheduled for the same timepoint, it is recommended that procedures be performed in the following seque nce: 
PROs, ECGs, vital signs, and blood draw .
jClinical safety laboratory tests : tests include hematology, chemistry, liver function , and other panels (ie, testosterone, PSA, albumin, alkaline phosphatase, and 
CD4 count; see Section 9.9). Tests w ill be done at every cycle, except for testosterone, and CD4 count (for HIV -positive subjects only), which are to be done at 
screening only. Required laboratory tests must be performed w ithin ±2 days of the scheduled visit.
kSparse PK sampling : blood samples for sparse PK sampling will be c ollected on Cycle 1 Day 1 and Cycle 2 Day 1 and will be obtained predose, and betw een 1 to 
3 hours and between 4 to 6 hours postdose in all subjects. On Cycle 1 Day 15, and on Day 1 of Cycles 3, 4, 5, and 7, blood sa mples for PK analysis will be 
obtained p redose only in all subjects.
lBiom arker collection on Cycle 1 Day 1: Circulating tumor cells, whole blood for RNA, and plasma for ctDNA samples are to be collected predose on Cycle 1 
Day 1.
mEoT visit: Circulating tumor cells, whole blood for RNA, and plasma for ctDNA sampling w ill occur at the time of radiographic progression or EoT visit 
(whichever is first).
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
35
Approved , Date: [ADDRESS_1044495]
LTE Long-term Extension
mCRPC metastatic castration -resistant prostate cancer
mCSPC metastatic castration -sensitive prostate cancer
MDS myelodysplastic syndrome
MedDRA Medical Dictionary for Regulatory Activities
MRI magnetic resonance imaging
NCI-CTCAE National Cancer Institute -Common Terminology Criteria for Adverse Events
ORR objective response rate 
OS overall survival
PALB2 Partner and Localizer of BRCA2 gene
PARP poly (adenosine diphosphate [ADP] -ribose) polymerase
PCWG3 Prostate Cancer Working Group 3
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
36
Approved , Date: 17 July 2020PK pharmacokinetic(s)
P-gp P-glycoprotein
PQC Product Quality Complaint
PR partial response
PRO patient -reported outc ome(s) 
PSA prostate specific antigen
RECIST Response Evaluation Criteria in Solid Tumors
RNA ribonucleic acid
rPFS radiographic progression -free survival
SAE serious adverse event
SAP statistical analysis plan
SSB single stranded break
SSE symptomatic skeletal event
TEAE treatment -emergent adverse event
ULN upper limit of normal
WHO World Health Organization
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
37
Approved , Date: 17 July [ZIP_CODE]. INTRODUCTION
Niraparib is an orally  available, highl y selective poly (adenosine diphosphate [ADP] -ribose) 
polymerase (PARP) inhibitor, with activity  against PARP -1 and PARP -2 deox yribonucleic acid 
(DNA) -repair polymerases.13Niraparib is being investigat ed for the treatment of ovarian, breast, 
and prostate tumors in patients with DNA- repair anomalies.
1.1. Background and Design Rationale
PARPs are enz ymes responsible for repair of DNA single -strand breaks (SSBs) through a process 
called base excision repair.1PARP inhibition leads to an accumulation of unrepaired SSBs, which 
result in stalling and collapse of replication forks and, consequentl y, to doubl
e-stranded breaks 
(DSBs). Normall y, DSBs are repaired through homologous recombination (HR). If not repaired, 
DSBs result in cell death. When tumor cells with DNA- repair defects involving the HR pathway  
(eg, Breast Cancer gene [BRCA]1, BRCA2) are treated w ith a PARP inhibitor, they  are unable to 
efficientl y and accurately  repair DSBs, which creates a synthetic lethal condition.2,7In men with 
metastatic castration -resistant prostate cancers (mCRPC), tumors with DNA
-repair anomalies 
account for approximately 20% to 30% of the sporadic cancers .9,[ADDRESS_1044496] of care for men with mCRPC was docetax el 
chemotherap y.4More recently , androgen receptor (AR) -targeted agents such as abiraterone acetate 
(ZYTIGA®) in combination with prednisone and enzalutamide (XTANDI®) have improved time 
to progression and survival rates, when indirectly  compared to docetaxel.10However, there 
remains a subset of patients who either do not respond, or become refractory  to these treatments. 
No approved therapeutic options are currently 
available for such patients. Platinum -based 
chemotherap y has been tested in a number of clinical studies in molecularly unselect ed prostate 
cancer patients with limited results and significant toxicities.[ADDRESS_1044497] -chemotherapy and AR -targeted agents.16Genetic sequencing 
identified homozy gous deletions, deleterious mutations, or both in DNA- repair genes, including, 
but not limited to BRCA1, BRCA2, Ataxia Telangiectasia Mutated gene (ATM), F anconi anemia 
genes, and Checkpoint Kinase 2 gene (CHEK2) in tumor samples.16Sixteen of 49 patients had a 
response (33%; 95% confidence interval [ CI]: 20%, 48%). Response was defined as one or more 
of the following: objective response, circulating tumor cell (CTC) conversion, or prostate specific 
antigen (PSA) decline ≤50%. Of these 16 patients, 14 (88%) had a response to olaparib and were 
biomarker -positive for anomalies in DNA -repair genes, including all 7 patients with BRCA2 loss 
(4 with biallelic somatic loss, and 3 with germline mutations) and 4 of 5 patients with ATM 
aberrations. Conversel y, only 2 of 33 biomarker -negative patient tumors (6%) had a response. 
Radiographic progression -free survival (rPFS) was significantl y longer in the biomarker -positive 
group than in the biomarker -negative group (median: 9.8 versus 2.7 months, respectivel y). Overall 
survival (OS) was also prolonged in the biomar ker-positive group versus the biomarker -negative 
group (median: 13.8 months versus 7.5 months, respectively ).
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
38
Approved , Date: [ADDRESS_1044498] version of the Investigator's Brochure.[ADDRESS_1044499] cancer, BRCA2 -deficient pancreatic cancer, and serous ovarian cancer.
Niraparib is not a potent inhibitor or inducer of cytochrome P450 (CYP) enzy mes; therefore, it is 
considered to have low potential to cause drug-drug interactions. However, preclinical data show 
that niraparib is a weak induce r ofCYP1A2 but not M1. Niraparib is a low clearance drug, and 
limited metabolism with involvement of multiple metabolic enzy mes (both CYPs and non- CYPs) 
was observed in vitro. Therefore, no major changes in niraparib pharmacokinetics (PK) are 
expected when co-administered with modulators of CYP enzy mes. Niraparib is a P-gp substrate. 
In animal studies, distributio n of niraparib to the central nervous system (CNS) was observed; 
however, niraparib had no effect on neurological function in a CNS safety  study using conscious 
mice. QTc interval was unaffected in anesthetized dogs; however, mean arterial pressure, heart 
rate, and QRS cardiac interval were increased. In repeat -dose toxicity  studies in rats and dogs, 
hematologic toxicities were observed but resolved by [CONTACT_762428] (typi[INVESTIGATOR_1306] y 
15to 28 day s).
Clinical Studies
Niraparib is currently  being investigated in ongoing Phase [ADDRESS_1044500] cancer. Niraparib has been evaluated in 144 subjects in Phase 1 studies (as a 
monotherap y and in combination). In Study PN001, 104 subjects with solid tumors, including 
subjects with prostate cancer (n=23) were evaluated at doses up to 400 mg once daily. 
Dose -proportional PK with an elimination half-life of 30 to 40 hours were observed. Antitumor 
activity  with niraparib was observed in subjects at dose levels ranging from 60 to 400mg. The 
dose limiting toxicity  at 400 mg once daily  was thrombocy topenia; the maximum tolerated dose 
and recommended Phase 2 dose for further development of niraparib was 300 mg.
In Study  PN001, all subjects (104) were reported with adverse e vents (AEs) and 90% of subjects 
were reported with drug-related AEs. Serious AEs (SAEs) were reported in 34% of subjects and 
10% of subjects were reported with drug-related SAEs. Only  3% of subjects discontinued 
treatment due to drug-related SAEs. The most common AEs (>30%) were nausea (57%), fatigue 
(56%), anemia (49%), constipation and vomiting (39% each), thrombocy topenia (35%), and 
decreased appetite (34%). The AEs responsible for discontinuation were electrocardiogram (ECG) 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
39
Approved , Date: 17 July 2020QT prolonged, fatigue, thrombocy topenia, intestinal obstruction, neoplasm malignant (disease 
progression), papi[INVESTIGATOR_044], pneumonitis, and vomiting. Six subjects died during the study : 4 due 
to disease progression, 1 due to sepsis, and 1 due to cerebral infarction. The safety  profile of 
niraparib demonstrates AEs primarily within the blood and l ymphatic and gastrointestinal Sy stem 
Organ Classes that are generally  mild to moderate in severity  and resolve with dose 
reduction/discontinuation.
1.3. Benefit/Risk A ssessment
Niraparib, administered as monotherapy , is anticipated to have a positive benefit -risk profile when 
used for the treatment of patients with mCRPC and DNA- repair anomalies, as proposed for this 
study . This assessment is based on the following:
During clinical development in subje cts with advanced solid tumors, the most common AEs 
(>25% of subjects) were nausea, fatigue, anemia, vomiting, thrombocy topenia, constipation, 
and decreased appetite. A small number of cases of my elodysplastic sy ndrome (MDS)/ acute 
myeloid leukemia (AML), including fatal cases, have been reported in clinical studies of 
niraparib. The safet y profile of niraparib demonstrates AEs that are generall y mild to moderate 
in severity  and are manageable with dose interruption or dose reduction. Preliminary  data 
obtai ned from the current study  suggest a similar profile in prostate cancer to the established 
safet y profile of niraparib in other indications, with no new safety  signals being observed to 
date.
Dose -proportional PK with an elimination half -life of 30 to 40 h ours were observed at doses 
up to 400 mg once daily in patients with solid tumors and with prostate cancer. Antitumor 
activity  with niraparib was observed in subjects at dose levels ranging from 60 to 400mg. The 
dose limiting toxicity  at 400 mg once daily was thrombocy topenia; the maximum tolerated 
dose and recommended Phase 2 dose for further development of niraparib was 300 mg.
While niraparib is an investigational agent in the metastatic prostate cancer population, it has 
been approved for the treatment of ovarian cancer. The safety  profile of niraparib has been 
characterized in clinical studies discussed in Section 1.2. Preliminary  data from sponsor 
studies sugg est that the safet y profile of niraparib in patients with metastatic prostate cancer 
is similar to that described in the Zejula®label.24,25Known toxicities for niraparib include 
gastrointestinal events, hematological events (ie, thrombocy topenia, neutropenia, anemia), 
and hypertension. These toxicities are managed by [CONTACT_762429], such as dose interruptions. The 
protocol also includes a targeted monitoring plan and treatment guidelines to ensure 
appropriate management of toxicit ies.
Given that the anticipated toxicities of niraparib are recognizable through medical oversight and 
laboratory  monitoring and are able to be managed medically, and there is a potential for increased 
efficacy  in patients with incurable mCRPC, the sponsor considers that there is a positive 
benefit/risk profile and strong rationale for evaluating niraparib, a PARP inhibitor, in  treatment of 
mCRPC patients with DNA -repair anomalies. 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
40
Approved , Date: 17 July [ZIP_CODE]. OBJECTIVES, ENDPOINTS/A SSESSMENTS, A ND H YPOTHESIS
2.1. Objectives and Endpoints /Assessments
Efficacy  objectives will be evaluated for subjects meeting the selection criteria that are described 
in Table 5.
Table 1: Study Objectives and Endpoints/Assessments
Objectives Endpoints/Assessments
Prim ary
 To assess the efficacy of niraparib in 
subjects with measurable mCRPC and 
who have either biallelic DNA -repair 
anomalies inBRCA (BRCA1 or BRCA2 ) 
or germline BRCA Objective response rate (ORR) of soft tissue (visceral or 
nodal disease) as defined by [CONTACT_762430] (RECIST) 1.1 with no evidence of bone 
progression according to the PCWG3 criteria20
Secondary
 To assess the efficacy of niraparib in 
subjects with measurable mCRPC and 
DNA -repair anomalies in biallelic non-
BRCA ( ATM FANCA, PALB2, CHEK2, 
BRIP1, or HDAC2 ) Objective response rate of soft tissue (visceral or nodal 
disease) as defined by [CONTACT_393] 1.1 with no evidence of 
bone progression according to the PCWG3 criteria20
 To assess the efficacy of niraparib in 
subjects with mCRPC and DNA -repair 
anomalies CTC response defined as CTC=[ADDRESS_1044501] -baseline in subjects with baseline CTC >0
 To evaluate response outcom es of 
niraparib in subjects with mCRPC and 
DNA -repair anomalies OS: time from enrollment to death from any cause
 As defined by [CONTACT_43877]3:20
 rPFS: time from enrollment to radiographic 
progression or death from any cause, whichever 
occurs first
 Time to radiographic progression
 Time to PSA progression 
 Time to symptomatic skeletal event (SSE)
 To evaluate the safety and tolerability of 
niraparib Incidence of adverse events
 Clinical laboratory test results
 To evaluate duration of tumor response  Duration of objective response: time from complete 
response (CR) or partial response (PR) to radiographic 
progression of disease, unequivocal clinical progression, 
or death, w hichever occurs f irst
Exploratory
 To assess the efficacy of niraparib in 
subjects with mCRPC and DNA -repair 
anomalies Response rate (RR): defined as 1 of the following by 
[CONTACT_43877]3:20
 Objective response (confirmed per RECIST 1.1), or
 Conversion of CTC from ≥5 cells per 7.5 mL blood 
at baseline to <5 cells per 7.5 mL blood nadir, 
confirmed by a second consecutive value obta ined 4 
or more weeks later, or
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
41
Approved , Date: 17 July 2020Objectives Endpoints/Assessments
 PSA decline of ≥50%, m easured tw ice 3 to 4 w eeks 
apart
 Time to unequivocal clinical progression
 To evaluate the population PK of niraparib 
and exposure -response relationships Analysis of niraparib oral clearance (CL/F), oralvolume 
of distribution (V/F), and derived measures of exposure 
(eg, area under the curve [AUC])
 Effect of demographic and physio -pathological covariates 
on niraparib PK parameters
 Analysis of relationships between exposure and safety or 
efficacy endpoints .
 To evaluate the steady -state PK of 
niraparib and its metabolite M1 Cmax, Tmax, Ctrough, AUC 0-24of niraparib and its metabolite 
M1 in a subset of subjects
 To evaluate the concordance betw een 
tissue -based and blood -based 
methodologies for detection of genomic 
alterations Com parison of gene alterations in DNA from tissue and 
in circulating tumor DNA (ctDNA) from plasma
 To evaluate potential DNA and RNA 
biomarkers predictive of response and 
resistance Changes in the levels or types of DNA and RNA 
biomarkers observed over time
 To evaluate the effect of niraparib on 
circulating tumor cells (CTCs) Changes in CTC counts observed over time
 To evaluate subject -relevant experiences 
(disease -related symptoms, treatment -
related symptoms, and health -related 
quality of life) Time to deterioration in subject -relevant experiences
Abbreviations: ATM=Ataxia Telangiectasia Mutated gene; AUC=area under the curve; BRCA1=Breast Cancer gene 1; 
BRCA2= Breast Cancer gene 2; BRIP1=BRCA1 Interacting Protein C-terminal Helicase 1 gene; CHEK2=Checkpoint 
Kinase 2 gene; CR=complete response; CTC=circulating tumor cell; ctDNA=circulating tumor DNA; 
DNA=deoxyribonucleic acid; FANCA=Fanconi Anemia Complementation Group A gene; HDAC2=Histone 
Deacetylase 2 gene; mCRP C=metastatic castration -resistant prostate cancer; ORR=objective response rate; OS=overall 
survival; PALB2=Partner and Localizer of BRCA2 gene; PCWG3=Prostate Cancer Working Group 3; PD=progressive 
disease; PK=pharmacokinetics; PR=partial response; PSA=pro state specific antigen; RECIST= Response Evaluation 
Criteria in Solid Tumors; rPFS=radiographic progression -free survival; RNA=ribonucleic acid; RR=response rate; 
SSE=symptomatic skeletal event.
Refer to Section 9, Study Evaluations for evaluations related to endpoints.
2.2. Hypothesis
Niraparib will demonstrate a >15% ORR in subjects with mCRPC and DNA- repair anomalies who 
have measurable disease.
3. STUDY DESIGN
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
[CONTACT_23774](s), which will be provided as a separate document.
This is a Phase 2, multicenter, open -label study  to assess the efficacy and safet y of once daily 
dosing of 300 mg niraparib in male subjects over the age of 18 years with mCRPC and DNA- repair 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
42
Approved , Date: [ADDRESS_1044502] received prior taxane -based chemotherap y and AR-targeted therap y. The 
study  will assess up to approximately  120subjects with measurable disease who are biomarker -
positive, as define in Section 9.7(approximately  75 subjects with DNA -repair anomalies inBRCA  
[BRCA1 o r BRCA2] and approximate ly 45subjects with biallelic DNA
-repair anomalies in non-
BRCA [ATM, FANCA, PALB2, CHEK2, BRIP1, or HDAC2 ]). In addition, at least 90 subjects 
with non-measurable disease (ie, bone disease only) regardless of their DNA  anomal y (ie,BRCA  
or non-BRCA) will be included to evaluate the activity  of niraparib in this population. Efficacy 
objectives will be evaluated for subjects meeting the selection criteria that are described in Table 5. 
All subjects will be monitored for safet y during the study  period, and up to 30days after the last 
dose of study  drug. Treatment will continue until disease progression, unacceptable toxicity , death,
or the sponsor terminates the study  (see Section 10).
The study  will consist of 5 phases; a Prescreening Phase ,a Screening Phase, a T reatment Phase, a 
Follow -up Phase , and a Long -term Extension Phase (see Section 9.1for details). 
4. SUBJECT POPULA TION
Male subjects over the age of 18 years with mCRPC and DNA- repair anomalies (biallelic 
mutations and germline pathogenic mutations only for BRCA1 or BRCA2 mutations) who 
received prior taxane -based chemotherap y and AR -targeted therapy (second -generation or later)
are eligible for the stud y.
4.1. Prescreening Eligibility Criteria
1. Signed prescreening informed consent form (ICF).
2. Criterion modified per Amendment 3.  
2.1. Criterion modified per Amendment 6.
2.2. Willing to provide a tumor tissue sample (archival or recentl y collected), and a blood 
sample for analy sis of DNA -repair anomalies using a sponsor -validated assay .
3. Criterion modified per Amendment 3.
3.1. Criterion modified per Amendment 5.
3.2. Criterion modified per Amendment 7.
3.[ADDRESS_1044503] 1 AR-targeted (second -generation or later) therap y.
4. Criterion modified per Amendment 3.
4.1. Criterion deleted per Amendment 4.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
43
Approved , Date: 17 July [ZIP_CODE].2. Inclusion Criteria
1. Male
2. >18 years of age (or the legal age of consent in the jurisdiction in which the study  is taking 
place).
3. Signed main study  ICF indicating that the subject understands the purpose of, and 
procedures required for , the study and is willing to participate in the study.
4. Criterion modified per Amendment 2.
4.1. Histologicall y confirmed prostate cancer (mixed histology  is acceptable, with the 
exception of the small cell pure phenoty pe, which is excluded).
5. Criterion modi fied per Amendment 2.
5.1. Criterion modified per Amendment 3.
5.2. Criterion modified per Amendment 5.
5.3. Criterion modified per Amendment 6.
5.4. Received a taxane -based chemotherap y for the treatment of metastatic prostate cancer 
with evidence of disease progression on or after treatment, or discontinued from a taxane -
based chemotherap y due to an adverse event.
6. Criterion modified per Amendment 2.
6.1. Criterion modified per Amendment 3. 
6.2. Criterion modified per Amendment 5.
6.3. Criterion modified per Amendment 6.
6.4. Criterion modified per Amendment 7.
6.5. Received a second -generation or later AR-targeted therap y (for example, abiraterone 
acetate plus prednisone, enzalutamide, apalutamide) for the treatment of metastatic 
prosta te cancer with evidence of disease progression or non-metastatic castration -resistant 
prostate cancer with evidence of subsequent metastasis.
7. Criterion modified per Amendment 3. 
7.1. Criterion modified per Amendment 7.
7.2. Biomarker -positive by  [CONTACT_196351] (see Section 9.7):
a.Biallelic DNA- repair anomaly  (refer toTable 5) based on a sponsor -validated 
blood or tissue assay .
b.Germline pathogenic BRCA1 or BRCA2 by [CONTACT_762420](somatic local results must 
be confirmed as positive by  [CONTACT_456]- validated assay  before dosing).
8. Criterion modified per Amendment 2.
8.1. Criterion modified per Amendment 4.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
44
Approved , Date: 17 July [ZIP_CODE].2. Progression of metastatic prostate cancer in the setting of castrate levels of 
testosterone ≤50 ng/dL  on a gonadotropin releasing hormone analog (GnRHa) , or hi story  
of bilateral orchiectom y at study  entry  defined as having one or more of the following:
a.PSA progression defined by  a minimum of 2 rising PSA levels with an interval 
of ≥1 week between each determination (per Prostate Cancer Working Group 3 
[PCWG3] criteria).20The PSA level at the screening visit should be ≥1μg/L 
(1ng/mL).
b.Radiographic progression of soft tissue by [CONTACT_393] 1.1 or bone disease by 
[CONTACT_43877]3 criteria20as defined below:
I. Soft tissue disease (measurable) by [CONTACT_393]  1.1 defined as having one 
or more of the following:
i.Nodal disease (pelvic or extrapelvic [retroperitoneal, 
mediastinal, thoracic, other]) with lesions ≥1.5 cm in the short 
axis.
ii.Visceral disease (lung, liver, adrenal) with lesions ≥1cm in the 
long axis.
II. Bone disease (non -measurable) defined as having bone lesions in the
absence of measurable soft tissue disease.
9. Must be able to continue GnRHa during the course of the stud y if not surgically castrate.
10. Eastern Cooperative Oncology  Group Performance Status (ECOG PS) of ≤2 (see 
Attachment 3).
11. Must be able to swallow whole capsules.
12. Subject must agree to use medically  accepted and highly  effective methods of 
contraception during the co urse of the study  and for [ADDRESS_1044504] dose of study 
drug.
13. To avoid risk of drug exposure through the ejaculate (even men with vasectomies), 
subjects must agree while on study  drug and for [ADDRESS_1044505] dose of study  
drug to:
a.Use a condom during sexual activity .
b.Not donate sperm.
14. Criterion modified per Amendment 2.
14.1. Criterion modified per Amendment 4.
14.2. Criterion modified per Amendment 5.
14.3. Criterion modified per Amendment 6.
14.4. At screening, the following laboratory  parameters must be met:
a.Absolute neutrophil count (ANC) ≥1.5 x 109/L
b.Hemoglobin ≥9.0 g/dL
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
45
Approved , Date: 17 July 2020c.Platelet count ≥100 x 109/L
d.Serum albumin ≥3 g/dL
e.Creatinine clearance ≥30 mL /min 
f.Criterion deleted per Amendment 5.
g.Serum total bilirubin ≤1.5 x upper limit of normal (ULN) or direct bilirubin 
≤1xULN (Note: in subjects with Gilbert’s syndrome, if direct bilirubin is 
≤1.[ADDRESS_1044506] may be eligible)
h.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
≤3.[ADDRESS_1044507]
i.CTC count of ≥1 cells/7.5 mL blood (required only for patients with 
non-measurable soft tissue disease b y RECIST 1.1)
4.3. Exclusion Criteria
1. Prior treatment with a PARP inhibitor.
2. Criterion modified per Amendment 2. 
2.1. Prior platinum -based chemotherap y for the treatment of prostate cancer.
3. Known history  or current diagnosis of myelody splastic syndrome (MDS)/acute myeloid 
leukemia (AML).
4. Criterion modified per Amendment 5.
4.1. Symptomatic or impending cord compression, except if subject has receive d 
definitive treatment for this and demonstrates evidence of clinicall y stable disease.
5. Criterion modified per Amendment 5.
5.1. Sy mptomatic brain metastases.
6. Known allergies, hypersensitivity , or intolerance toniraparib or its excipi[INVESTIGATOR_840] (refer to 
Investigator's Brochure).[ADDRESS_1044508] (eg, compromise the well -being) or that 
could prevent, limit, or confound the protocol -specified assessments.
8. Known disorder affecting gastrointestinal absorption.
9. Active cancer (other than prostate cancer; or basal cell or squamous cell skin cancer, 
non-muscle invasive bladder cancer [stages pTaG1 and pTaG2], or any  other cancer in 
situ currently  in complete remission) within 2 y ears prior to Cy cle 1 Day 1.
10. Criterion modified per Amendment 5.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
46
Approved , Date: 17 July 202010.1 Prior palliati ve radiotherapy  ≤7 days prior to Cycle 1 Day 1. Radiotherap y given 
>[ADDRESS_1044509] resolved to Grade 1 or baseline.
11. Criterion modified per Amendment 2.
11.1. Criterion deleted per Amendment 5
12. Criterion deleted per Amendment 3.
13. History  of clinically  significant ventricular arrhythmias (eg, ventricular tachycardia, 
ventricular fibrillation, torsades de pointes).
14. HIV-positive subjects with 1 or more of the fo llowing:
a.Not receiving highl y active antiretroviral therap y
b.A change in antiretroviral therap y within 6 months of the start of screening 
(except if, after consultation with the sponsor on exclusion criterion 14.c, a 
change is made to avoid a potential drug -drug interaction with the stud y drug)
c.Receiving antiretroviral therap y that may interfere with the study  drug (consult 
the sponsor for review of medication prior to enrollment)
d. CD4 count <350 at screening
e.An acquired immunodeficiency  syndrome -defining opportunistic infection 
within 6 months of the start of screening
15. Criterion modified per Amendment 2.
15.1. Criterion modified per Amendment 6.
15.2. ≤14 day s prior to Cy cle 1 Day  1 had:
a.a transfusion (platelets or red blood cells)
b.chemotherap y
c.hematopoietic growth factors
16. Criterion deleted per Amendment 5.
17. Criterion modified per Amendment 5.
17.1. Subjects with uncontrolled (persistent) hypertension defined as systolic blood 
pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg despi[INVESTIGATOR_72604].
5. TREA TMENT ALLOCA TION AND BLINDING
This is an open -label, single -treatment study ; therefore, blinding and randomization procedures 
are not applicable.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
47
Approved , Date: 17 July [ZIP_CODE]. DOSA GE A ND A DMINISTR ATION
For the purpose of this study , ‘study  drug’ refers to niraparib. All dosing information must be 
recorded in the electronic case report form (eCRF). The [ADDRESS_1044510] cancer.
6.1. Study Drug Administration
The study  drug, nirapari b 300 mg, will be provided as capsules (3 x 100 mg) for once daily oral 
administration. The capsules must be swallowed whole. Subjects should take their dose in the 
morning (with or without food) . Although not considered study  medication, subjects who have not 
undergone surgical castration must continue to receive regularl y prescribed GnRHa. Contact [CONTACT_103]’s medical monitor if interruption of GnRHa is required. All GnRHa therapi[INVESTIGATOR_762412].
A treatment cycle is defined as [ADDRESS_1044511] remembers within an approximate 12-hour window. Otherwise, subjects should take the 
next dose the following day, without compensating for the missed dose. Missed doses should be 
recorded in the eCRF.
6.2. Dose Modification and Management of Toxicity
All dose interruptions and dose reductions (including missed doses) and the reason for the 
interruption/reduction are to be recorded in the eCRF. Management of toxicities should be 
performed as detailed in Sections 6.2.[ADDRESS_1044512] be discussed in advance with the sponsor’s medical 
monitor. 
6.2.1. Non- hematologic Toxicities
For subjects who develop drug-related Grade [ADDRESS_1044513] for further evaluation if they meet any 
of the following criteria:
QTcF on ECG >480 msec at an y visit. 
Persistent hy pertension ≥Grade 3 despi[INVESTIGATOR_762413].
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
48
Approved , Date: 17 July 2020Table 2: Dose reduction for Drug -related Non -hematologic Toxicities
Event Restarting Dose
After first Grade 3 or 4 treatment -related SAE/AE 200 mg QD
After second Grade 3 or 4 treatment -related SAE/AE [ADDRESS_1044514] Grade 3 or 4 treatment -related SAE/AE for ≥[ADDRESS_1044515] sponsor
QD=once daily; SAE/AE=serious adverse event/adverse event
[IP_ADDRESS]. Hepatic Toxicities
Hepatic toxicities are known potential side effect of niraparib.12Table 3provides dose 
recommendations for subjects who develop liver function test (LFT) abnormalities during 
treatment with niraparib. During dose interruptions, LFTs should be monitored at least weekl y. 
For Grade ≥[ADDRESS_1044516] weekly  until Grade 1 or 
baseline. For subje cts being retreated, serum transaminases should be monitored at a minimum of 
every  2 weeks for 3 months and monthly  for the next 3 months.
Table 3: Dose Modification Criteria for AST/ALT/Bilirubin Abnorm alities for Niraparib
Toxicit y Grade Dose of Niraparib
Grade [ADDRESS_1044517]/ALT/bilirubin are confirmed 
Grade [ADDRESS_1044518] be interrupted and discussed with medical monitor.a
ALT=alanine aminotransferase; AST=aspartate aminotransferase
a Must be discussed with medical monitor prior to any restart.
If clinical symptoms or signs suggestive of hepatotoxicity  develop, serum transaminases should 
be measured immediately . If a subject develops severe hepatotoxicity  (ALT or AST >20 x UL N) 
anytime while receiving niraparib, subjects should be discontinued from treatment and retreatment 
should not be attempted. Re -escalation of niraparib is not permitted if the dose reduction was due 
to elevated LFTs.
Subjects who develop a concurrent elevation of ALT >3 x UL N and a total bilirubin >2 x UL N in 
the absence of biliary  obstruction or other causes responsible for the concurrent elevation should 
be permanently  discontinued from the study  drug treatment.
6.2.2. Hematologic Toxicities
Dose interruption/modification criteria for hematologic toxicities will be based on the blood counts 
outlined in Table 4. If dose interruption or modification is required at any point on study  due to 
hematologic toxicity , weekly  blood draws for complete blood count (CBC) will be monitored until 
AE resolution (t o the specified levels in Ta ble 4). To ensure safet y of the new dose, weekl y blood 
draws for CBC will also be required for an additional 28 days after AE resolution, after which, 
monitoring per the Time and Events Schedule may resume.
Study  drug dose modification/reduction criteria for thrombocy topenia and neutropenia will be 
based on the criteria outlined in Table 4. For the management of anemia, supportive measures such 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
49
Approved , Date: [ADDRESS_1044519] of care. If more than 1 blood transfusion is given within 4 weeks, the sponsor should be 
notified. For Grade ≥3 anemia, study  drug should be interrupted until resolution to <Grade 3, and 
restarted after discussion with the sponsor to determine if a dose level reduction is required.
The site should contact [CONTACT_762431] 1 or baseline after 28days of dose interruption, 
or a diagnosis of MDS/AML  is confirmed by  a hematologist. 
Table 4: Dose Modification/Reductions for Hem atologic Toxicity (Platelet Count and Neutrophil Count)
Toxicity Grade Dose of Niraparib
Grade [ADDRESS_1044520] weekly monitoring and consider int errupting until 
≤Grade 1 or baseline and then resume at same dose w ith 
recommendation of weekly monitoring for 28 days after 
restart. 
Grade ≥3 Interrupt until ≤Grade 1 or baseline, then:
If subject w as on 300 mg, restart at 200 mg (ie, 1 dose 
level reduction)a
If subject w as on 200 mg dose, resume at 200 mg or 
100mg if there w as rapid decline in the hematologic 
parameter soon after initiation of niraparib, as judged 
by [CONTACT_093]
If subject w as on 100 mg, permanently discontinue 
study drug
Weekly monitoring for 28 days is recommended after 
restarting dose.
Second occurrence Grade ≥3 Interrupt until ≤Grade [ADDRESS_1044521] occurrence Grade ≥3 Perm anently discontinue. 
aFor each dose -level reduction, decrease dose by 100 mg or 1 capsule of niraparib.
Notes:
 For subjects with a platelet count ≤10,000 cells/ µL, prophylactic platelet transfusion per guidelines may be 
considered. For subjects taking anti-coagulant or anti-platelet therapy, consider the risk/benefit of 
interrupting these drugs or prophylactic transfusion at an alternative threshold such as ≤ 20,00 0 cells/ µL.
 Supportive measures like blood transfusions may be performed as deemed necessary by [CONTACT_093].
 Weekly monitoring and/or interruption are not required if values return to baseline levels.
 If subject requires platelet transfusion or has ne utropenic fever or neutropenia requiring granulocyte -colony 
stimulating factor deemed to be related to niraparib toxicity, restart at [ADDRESS_1044522] 24 hours prior to planned procedures that require 
hospi[INVESTIGATOR_762414] 1 or resolved.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
50
Approved , Date: 17 July [ZIP_CODE]. TREA TMENT COMPLIA NCE
A count of all study  drug provided by [CONTACT_762432] . Study  drug will be dispensed and dosing compliance will be assessed at study  visits 
as described in the Time and Events Schedule. In the absence of toxicity, if the dosing compliance 
is not 100%, then investigators or designated study -site personnel should re-instruct subjects 
regarding proper dosing procedures and the subject may  continue study treatment.
The study  site must maintain accurate records demonstrating dates and amount of study  drug 
received, to whom dispensed (subjec t-by-subject accounting), and accounts of any study drug 
accidentally  or deliberately  destro yed. The amount of study  drug dispensed will be recorded and 
compared with the amount returned. At the end of the study, reconciliation must be made between 
the amount of study  drug supplied, dispensed, and subsequently  destro yed or returned to the 
sponsor or its representative (see also Section 14.5 ).
8. CONCOMITA NT THERA PY
Concomitant therapi[INVESTIGATOR_762415] [ADDRESS_1044523] be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730]:
1.Chemotherapeutic, biologic, hormonal (exception: subjec ts must continue GnRHa 
during the course of the study  if not surgically  castrate), or other agents with 
antitumor effect against prostate cancer.
2.Live virus vaccines. An increased risk of infection by  [CONTACT_762433] . Effects with niraparib 
are unknown and therefore live virus vaccines should not be administered. Note that 
inactivated bacterial and virus vaccines are permitted.
8.2. Restricted Concomitant Medications
1.Niraparib is a weak induce r ofCYP1A2 in vitro; therefore, caution should be used 
with drugs that are sensitive substrates of CYP1A2 or moderately  sensitive substrates 
of CYP1A2 with a narrow therapeutic range (refer to the Investigator’s Brochure12; 
for additional information, see Attachment 5).
2.Although no large changes in the mean QTc interval (>20 msec) were detected in a 
study  following the treatment of niraparib 300 mg once daily, caution should be used 
for medications that could potentially  cause QT prolongation or torsades de pointes.17
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
51
Approved , Date: 17 July [ZIP_CODE]. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy , PK, biomarker, 
Patient- reported Outcomes (PRO), and safet y measurements applicable to this study . Medical 
resource utilization data will also be collected; refer to Section 9.8fordetails.
If multiple assessments are scheduled for the same timepoint, it is recommended that procedures 
be performed in the following sequence: PROs, ECGs, vital signs, and blood draw. Blood 
collections for PK assessments should be kept as close to the specified time as possible. Other 
measurements may  be done earlier than specified timepoints if needed. Actual dates and times of 
assessments will be recorded in the source documentation and eCRF.
For each subject, the maximum amount of blood drawn will not exceed [ADDRESS_1044524] is biomarker -positive for 
DNA- repair anomalies (see Section 9.7). All subjects will be required to sign a specific ICF for 
the Prescreening Phase and provide baseline demographic characteristics and disease -specific 
medical history . The Prescreening Phase may occur at an y time for subjects with mCRPC prior to 
the Scre ening Phase.
During the Prescreening or Screening Phase, a blood sample will be collected. I n addition, a tumor 
tissue sample (either archival or recently  collected) should also be collected. If no tumor tissue is 
available, then the subject will be asked to have a new tumor tissue sample collected. Tissue 
(archival or recentl y collected) may also be used to determine eligibility.
If the subject is biomarker -positive by  [CONTACT_456] -validated blood -or tissue -based assay , then he 
is eligible to enter the Screening Phase .Subjects who are positive for pathogenic BRCA1 or 
BRCA2 mutations based on local test results ( somatic or germline ) can enter the Screening Phase .
AEs and SAEs related to the blood or recent tissue collection procedures will be collected for 
30days after the procedures. Tissue samples collected during the Prescreening Phase will be 
analyzed for concordance with the blood -based sample results.
9.1.3. Screening Phase
All biomarker -positive subjects must sign the main study  ICF prior to the conduct of any 
study -related procedures in the Screening Phase. Subjects who are positive for germline 
pathogenic BRCA [ADDRESS_1044525] results (blood or saliva) can be 
screened and enter the treatment phase and subjects who are positive for somatic pathogenic 
BRCA 1 or BRCA2 mutations (blood, saliva, or tissue) based on local results must be confirmed 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
52
Approved , Date: [ADDRESS_1044526] sign a new ICF before rescreening. Subjects rescreened within 28days of planned enrollment 
may use the initial screening laboratory  results, computed tomograph y (CT)/magnetic resonance 
imaging (MRI) and bone scans (if still within 8 weeks of Cycle 1 Day 1) to determine eligibility  
if not the reason for the rescreening.
9.1.4. Treatment Phase
The Treatment Phase will begin at Cycle [ADDRESS_1044527] measurements taken on Day 1 of C ycle1 before administration of the study 
drug or at screening (whichever value was last) will be defined as the baseline values. Visits for 
each cy cle will have a ±[ADDRESS_1044528] 
imaging performed within ±[ADDRESS_1044529] not take the study  drug at home on the morning of study  
visits. Study  drug should be taken at the site. Details of PK sampling day s and times are provided 
in the Time and Events Schedule. Additional details regarding PK sampling are provided in 
Section 9.3 . Details of blood sample handling and storage procedures for PK are provided in the 
laboratory  manual.
Clinical evaluations and laboratory  studies may be repeated more frequently , if clinicall y 
indicated. Study  drug treatment will continue until disease progression, unacceptable toxicity , 
death, or the sponsor termi nates the study  (see Section 10). Once the subject discontinues study  
drug, the subject must complete the End-of- Treatment (EoT) visit within 30(±5) days after the 
last dose of study  drug, and enter the Follow -up Phase. (Note: for subjects with a dose interruption 
who discontinue study  drug, the EoT visit must occur within 30[±14] day s after the last dose of 
study  drug).
9.1.5. End-of-Treatment Visit
An EoT visit must occur 30 (±5) days after the last dose of study  drug or prior to administration 
of a new anti-prostate cancer therapy , whichever occurs first. (Note: for subjects with a dose 
interruption who discontinue study  drug, the EoT visit must occur within 30[±14] day s after the 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
53
Approved , Date: [ADDRESS_1044530] dose of study  drug). If a subject is unable to return to the site for the EoT visit, the subject 
should be contact[CONTACT_762434] [ADDRESS_1044531], MRI , or bone scans (99mTc) will be collected every 3 months (12weeks 
±2weeks) from the EoT visit until confirmed radiographic progression, provided the subject has 
not started a subsequent treatment for prostate cancer and does not withdraw consent. If a subject 
has documented radiographic progression during the Treatment Phase, additional radiographic 
assessments are not required during the Follow -up Phase. In addition, survival follow -up and SSEs 
will be performed every  3months (12weeks ±2weeks) either via clinic visits, telephone 
interview, chart review, or other convenient methods. Deaths regardless of causality  and SAEs 
thought to be related to study  drugs (including diagnosis of MDS/AML) will be collected and 
reported within [ADDRESS_1044532] be 
available fo r review in the source documents.
9.1.7. Long -term Extension Phase
See Attachment 7for the criteria for participation and procedures to be performed duringthe 
Long -term Extension Phase.
9.2. Efficacy
9.2.1. Evaluations
Efficacy  evaluations will be conducted as specified in the Time and Events Schedule. Unscheduled 
assessments should be considered if clinically  indicated, and results collected in the eCRF. The 
efficacy  evaluations inc lude the following:
Tumor measurements: 
Chest, abdomen, and pelvis CT or MRI scans and whole body  bone scans (99mTc). The 
same imaging modality  should be used throughout the evaluation of an individual subject. 
Imaging will be assessed by [CONTACT_762435]. Scans will also be collected and stored by  a central vendor for central 
review if indicated.
serum PSA
CTC
survival status
SSEs
9.2.2. Endpoint Criteria
Objective response of soft tissue (visceral or nodal disease) is defined by [CONTACT_762436] T umors (RECI ST) 1.1 (see Attachment 2) with no evidence of bone progression 
on bone scan according to the PCWG3 criteria:
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
54
Approved , Date: 17 July 2020Tumor response of soft tissue lesions will only be evaluated for subjects with baseline 
measurable disease assessed by  [CONTACT_762437] 1.1.
After first documentation of soft tissue response (CR or PR), repeat imaging is required 
4weeks later (+ 2-week window) for confirmation per RECI ST 1.1. The schedule for 
subsequent scans will be based upon Cycle [ADDRESS_1044533] 1.1 for 
soft tissue disease and PCWG3 for bone disease as follows: 
Progression of soft tissue lesions measured b y CT or MRI  as defined in RECI ST 1.1.
Progression by [CONTACT_762438]3.20Bone progression 
is defined as one of the following, depending on what is observed at the Week 8 scan and what 
is observed on the confirmatory  scan (which is performed ≥6 weeks later) :
1.
Subject whose Week [ADDRESS_1044534] ≥2 new bone lesions compared with the 
baseline scan would fall into one of the 2 categories below:
a. Subject whose confirmatory  scan shows ≥2 new lesions compared with the Week 8 
scan (ie. a total of ≥4 new lesions compared with the baseline scan) will be considered 
to have bone scan progression at Week 8.
b. Subject whose confirmatory  scan did not show ≥[ADDRESS_1044535] scan timepoint that shows ≥2 new lesions compared with the Week 8 scan will 
be considered as the bone scan progression timepoint if these new lesions are 
confirmed b y a subsequent scan ≥[ADDRESS_1044536] ≥[ADDRESS_1044537] scan timepoint that shows ≥2 new lesions compared with the Week 8 scan 
will be considered as the bone scan progression timepoint if these new lesions are 
confirmed b y a subsequent scan ≥[ADDRESS_1044538] 1.1 (see Attachment 2). The duration of tumor response will be 
assessed from the first time of observed CR/PR to the date of radiographic progression, 
unequivocal c linical progression, or death, whichever occurs first.
See Section 10.1 for details regarding discontinuation of study  medication for disease progr ession.
9.3. Pharmacokinetics
9.3.1. Sample Collection and Handling
Sparse PK sampling will be collected from all subjects in this study . Blood samples to measure 
plasma levels of niraparib and its metabolite, M1, will be obtained on Cy cle 1 Day  1 and Cy cle 2 
Day 1 atpredose, and between 1 to 3 hours and between 4 to 6 hours postdose. 
On Cycle1 Day 15, 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
55
Approved , Date: 17 July 2020and on Day 1 of Cycles 3, 4, 5, and 7, blood samples for PK analysis will be obtained predose only 
in all subjects as per the Time and Events Schedule.
Other metabolit e(s) of niraparib may also be measured in collected PK samples. Other 
measurements may be done earlier than the specified timepoints if needed. Actual dates and times 
of dose administration and assessments, as well as date and time of previous dose will be recorded 
in the laboratory  requisition form. Note that if a visit has pre-or postdose samples, the date and 
time of the [ADDRESS_1044539] 
be recorded. Refer to the laboratory  manual forsample collection requirements, shippi[INVESTIGATOR_3930], and specified controlled temperatures for storage.
9.3.2. Analytical Procedures
Plasma samples will be analy zed to determine concentrations of niraparib and its metabolite, M1, 
using a validated, specific, and sensitive assay  method by, or under the supervision of, the sponsor. 
If other metabolite(s) are analy zed quantitativel y in the plasma samples, plasma concentration of 
the metabolites will be reported.
After completion of quantitative analy sis, the remai ning plasma samples will be stored at -70°C 
for investigative metabolite identification/profiling as deemed necessary by [CONTACT_456] (to be 
reported separatel y from this study ).
9.3.3. Pharmacokinetic Parameters
Based on the individual plasma concentration -time data, using the actual dose taken and the actual 
sampling times, PK parameters and exposure of niraparib will be derived using population PK 
modeling. Baseline covariates (eg, body  weight, age, creatinine clearance, race) may be included 
in the model, if relevant. Data from this stud y may be pooled with data from other clinical studies.
9.4. Patient -reported Outcomes
The goal of collecting PRO data is to explore if subjects experience treatment benefits in pain, 
fatigue, and or functional status. PROs will be measured utilizing the Brief Pain Inventory -Short 
Form questionnaire (BPI -SF), the Functional Assessment of Cancer Therap y-Prostate 
questionnaire (FACT -P), and the Euro -QoL questionnaire (EQ-5D- 5L). All visit-specific PRO 
assessments are strongl y encouraged to be conducted and completed before any tests, procedures, 
or other consultations for that visit. The PRO assessments will be captured on paper and results 
entered into the eCRF. Detailed instructions for administering the PRO questionnaires will be 
provided in a PRO manual.
9.4.1. BPI-SF
The BPI -SF (24 -hour recall) includes a front and back bod y diagram for the subject to identify the 
location of his pain. The interference items measure how much pain has interfered with recent 
daily  activities, including general activity , walking, work, mood, enjoy ment of life, relations with 
others, and sleep. BPI [INVESTIGATOR_762416] 7 interference items.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
56
Approved , Date: [ADDRESS_1044540]’s self-reported functional status, 
well-being, and prostate cancer -related sy mptoms. The FACT -P questionnaire includes a general 
functional status scale (consisting of 4 subscales: physical well- being, social and family 
well-being, emot ional well-being, and functional well-being) and a prostate cancer -specific 
subscale with items including urination, bowel movement, and erectile function. Total score is 
calculated with general function and prostate -cancer -specific scores and ranges from 0 to 156 
(higher scores indicate better functional status).
9.4.3. EQ-5D-5L
The EQ-5D- 5L is a standardized measure of health status developed by [CONTACT_73474] a simple, generic measure of health for clinical and economic appraisal ( EuroQoL  Group, 
1990). The EQ-5D- 5L is composed of the following 5 dimensions: mobility , self-care, usual 
activities, pain/discomfort, and anxiety /depression. Each dimension has 5 levels: no problems, 
slight problems, moderate problems, severe problems, and unable to/extre me problems. The EQ 
visual analog scale records the respondents’ self -rated health as ‘Best imaginable health state’ and 
‘Worst imaginable health state’ .
9.5. Pharmacody namics
Pharmacod ynamics assessment was removed per Amendment 3.
9.6. Pharmacokinetic/Pharmacody namic Evaluations
Exposure -response relationship will be explored for key efficacy  (eg, RR, PSA) and safet y 
parameters as data allow.
9.7. Biomarkers
To be included in the primary  efficacy  population, subjects must be confirmed to be either biallelic 
BRCA (BRCA1 or BRCA2 )by a sponsor -validated blood- or tissue -based assay  orhave a 
germline pathogenic BRCA (BRCA1 or BRCA2 )mutation (archival or recentl y collected), see 
Section 9.1.[ADDRESS_1044541] for this study  are listed in Table 5. 
Table 5: Biom arker Panel
Genes Definition
BRCA1 Breast Cancer gene [ADDRESS_1044542] Cancer gene 2
FANCA Fanconi Anemia Complementation Group Agene
PALB2 Partner and Localizer of BRCA 2gene
CHEK2 Checkpoint Kinase 2gene
BRIP1 BRCA1 Interacting Protein C -terminal Helicase 1gene
HDAC2 Histone Deacetylase 2gene
ATM Ataxia Telangiectasia Mutated gene
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
57
Approved , Date: 17 July [ZIP_CODE].7.1. Evaluations
Biomarker evaluations will be conducted as specified in the Time and Events Schedule and are 
described in Sections [IP_ADDRESS] to [IP_ADDRESS] .
[IP_ADDRESS]. Tissue A nalysis
Tumor tissue (either archival or recently  collected) should be obtained to evaluate DRD status, and 
may also be used to identify  markers associated with disease evolution, immune context, or 
response to study  drugs. Tissue samples collected at screening may be used for concordance and 
bridging studies for the development of the assay . Furthermore, tumor tissue may  be assessed for 
RNA signatures predictive of response to niraparib.
[IP_ADDRESS]. Circulating Tumor Cells
Blood samples for CTC enumeration will be collect ed at timepoints specified in the Time and 
Events Schedule. CTC enumeration will be evaluated at the central laboratory , to assess response 
to study  drug.
[IP_ADDRESS]. Whole Blood for RNA
Whole blood samples will be collected as specified in the Time and Events Schedule. Multiple 
ribonucleic acid (RNA) transcripts found in prostate tumors are detectable in the RNA and analysis 
of these samples will allow evaluation of potential mechanisms of resistance that may emerge with 
niraparib.
[IP_ADDRESS]. Circulating Tumor DNA
Plasma samples collected during the course of treatment may beused to screen for changes in the 
levels or ty pes of DNA -repair anomalies observed over time by  [CONTACT_762439] (ctDNA), 
and to monitor for potential markers of resistance to niraparib. Samples collected at screening and 
Cycle 1 Day 1 m ay be used for concordance and bridging studies with tumor tissue as well as 
development of the assay.
[IP_ADDRESS]. Saliva Testing
Testing via a saliva sample may be collected to evaluate for germline mutations. Subjects will be 
permitted to be screened and enter the treatment phase if positive for BRCA1 or BRCA2 germline 
pathogenic mutations.
9.8. Medical Resource Utilizat ion
Medical resource utilization data, associated with medical encounters, will be collected in the 
eCRF by [CONTACT_70449] -site personnel for all subjects throughout the study . 
Protocol -mandated procedures, tests, and encounters are excluded. T he data collected may be used 
to conduct exploratory economic anal yses and will include:
Number and duration of medical care encounters, including surgeries, and other selected 
procedures (inpatient and outpatient).
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
58
Approved , Date: 17 July 2020Duration and cause of hospi[INVESTIGATOR_059] (total day s length of stay , including duration by  [CONTACT_54006]; 
eg,intensive care unit).
Number and character of diagnostic and therapeutic tests and procedures.
Outpatient medical encounters and treatments (including physician or emergency  room visits, 
tests and procedures, and medications).
9.9. Safety
Safety  assessments will be based on medical review of AE reports and the results of vital sign 
measurements, ECGs (12-lead), physical examinations, clinical laboratory  tests, ECOG PS, and 
other safet y evaluations at specified timepoints as described in the Time and Events Schedule. Any 
clinically  significant abnormalities persisting at the EoT visit will be followed by  [CONTACT_762440], whichever comes first.
Adverse Events
AEs will be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, or the subject's 
legally  acceptable representative) for the duration of the study . AEs will be followed by [CONTACT_290152] 12, Adverse Event Reporting.
Clinical Laboratory Tests
Blood samples to assess the safet y of study  drug will be collected. The investigator must review 
laboratory  results, document this review, and record any clinically  relevant changes occurring 
during the study  in the AE section of the eCRF. For each laboratory  abnormality  reported as an 
AE, the following laboratory  values should be reported in the laboratory  section of the eCRF: the 
value indicative of the onset of each toxicity  grade; the most abnormal value observed during the 
AE, and the value supporting recovery  to Grade [ADDRESS_1044543] be performed within ±2 days of the scheduled visit. I n the event of 
additional safet y monitoring, unscheduled laboratory assessments may be performed as required.
For any suspected MDS/AML  case reported while a subject is receiving treatment or being 
followed for post-treatment assessments, bone marrow aspi[INVESTIGATOR_762417] a local hematologist. A whole blood sample will also be collected for cytogenetic 
analysis (mutations of select my eloid- associated genes). Testing completed as part of standard of 
care is sufficient as long as the methods are acceptable to the sponsor's medical monitor. The study 
site must receive a copy of the hematologist’s report of aspi[INVESTIGATOR_337]/biopsy  findings, which must 
include a classification according to World Health Organization (WHO) criteria,22and other 
sample testing reports related to MDS/AML . Data from the report will be entered on the 
appropriate eCRF pages and the site must keep a copy of the report w ith the subject’s study  file.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
59
Approved , Date: 17 July 2020The following tests will be performed b y the central laboratory as outlined in the Time and Events 
Schedule:
Hematology  Panel
-CBC (hemoglobin, white blood cell count, platelets, absolute ly mphocy te count, and ANC)
Serum Chem istry Panel
-sodium -lactate deh ydrogenase 
-potassium -calcium
-creatinine -glucose
-magnesium -uric acid
-inorganic phosphorus -gamma glutamy ltransferase
-total protein -chloride
-blood urea nitrogen
Liver Functions Tests
-AST -ALT
-total bilirubin (if above normal, measure 
direct bilirubin)
Other Laboratory  Tests
-testosterone (screening only ) -PSA
-albumin -alkaline phosphatase
-CD4 count for HIV -positive subjects only  
(screening onl y)
Electrocardiogram (ECG)
Standard 12-lead ECGs will be recorded at the timepoints outlined in the Time and Events 
Schedule. Any known electroly te imbalance should be treated prior to performing the ECG. ECGs 
should be recorded on the same device, if at all possible, to avoid ECG device variabilit y. 
Computer -generated interpretations of ECGs should be reviewed for data integrit y and 
reasonableness by [CONTACT_093]. Subjects are to reside in a quiet setting without distractions (eg, 
television, cell phones, and staff talking) at each scheduled timepoin t for ECG measurements. 
Subjects should rest in a supi[INVESTIGATOR_21683] [ADDRESS_1044544]’s medical history  and recorded on the eCRF. 
Clinically  significant abnormalities noted during the Treatment Phase and at the EoT visit will be 
recorded on the Adverse Event section of the eCRF.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
60
Approved , Date: [ADDRESS_1044545], height and weight, examination of the skin, ears, nose, throat, lungs, heart, abdomen, 
extremities, musculoskeletal system, lymphatic system, and nervous system. During the Treatment 
Phase and at the EoT visit, limited symptom -directed physical examination and weight assessment 
is required. Only clinically  relevant abnormalities found on physical examination should be 
recorded and reported as AEs in the eCRF.
ECOG Performance Status
The ECOG PS scale (provided in Attachment 3) will be used to grade changes in the subject’s 
daily  living activities. The frequency of ECOG PS assessment is provided in the Time and Events 
Schedule.
9.10. Sample Collection and Handling
The actual dates and times of sam ple collection must be recorded in the laboratory  requisition 
form. Refer to the Time and Events Schedule for the timing and frequency  of all sample collections. 
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided.
10. SUBJECT COMPLETION/W ITHDRA WAL
10.1. Discontinuation of Study Treatment
A subject will not be automatically  withdrawn from the study  if he discontinues study  drug.
Subjects who discontinue study drug should complete the EoT visit within 30(±5) days of the last 
dose of study  drug or the end of the dose interruption period since the last dose of study  drug. 
Subjects should ordinarily  be maintained on study  treatment until confirmed radiographic 
progression. If the subject hasradiographic progression but no unequivocal clinical progression 
and alternate treatment is not initiated, the subject may continue on study  treatment, at the 
investigator’s discretion. Study  treatment will be continued for subjects who have increasing PSA 
values in the absence of radiographic or unequivocal clinical progression. Although serial PSA’s 
will be measured on this study , progression or change in PSA values is not considered a reliable 
measure of disease progression, and should not be used as anindication to discontinue study  
therap y.20However, a subject's stud y treatment must bediscontinue d for:
Study  drug -related toxicity  as defined i n Section 6.2.
Unequivocal clinical progression defined as:
Deterioration in ECOG PS to Grade 3 or higher.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
61
Approved , Date: 17 July 2020Need to initiate any of the following because of tumor progression (even in the absence 
of radiographic evidence of disease):
oAlternative anticancer therap y for prostate cancer.
oRadiation therap y.
oSurgical interventions for complications due to tumor progression.
Clinically  significant QTcF ≥5 00 ms or QTc prolongation >60 ms above baseline.
Diagnosis of MDS/AML.
Treatment -related h ypertensive crisis or posterior reversible encephalopathy  syndrome
The investigator believes it is in the best interest of the subject to discontinue study  drug.
With drawal of consent for continued treatment (subject’s decision to discontinue for any 
reason).
Palliative radiation therapy  for bone pain may not require a subject to be discontinued from 
treatment, after discussion with the medical monitor. Note: subjects who discontinue study  
treatment for any reason remain on study  and must follow all study  evaluations described in 
Section 9and outlined in the Tim e and Events Schedule.
10.2. Withdrawal from the Study
A subject will be considered withdrawn from the study  (ie, Treatment Phase ,Follow -up Phase , 
Long -term Extension Phase ) for an y of the following reasons:
Lost to follow -up 
Withdrawal of consent for subsequent data collection
Study  is terminated by  [CONTACT_762441] a subject is lost to follow -up, effort must be made by [CONTACT_1758] -site personnel to contact [CONTACT_762442]/withdrawal. The 
measure s taken to follow up must be documented in the subjects ’source documents. The informed 
consent will stipulate that even if a subject decides to discontinue the study drug, he will agree to 
be contact[CONTACT_762443] s tatus. This can be done by 
[CONTACT_756] ,by [CONTACT_14716] ,or by [CONTACT_762444]. If the 
subject withdraws consent for all study -related procedures, then no further contact [CONTACT_762445], except as permitted by  [CONTACT_427].
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study  drug assigned to the withdrawn subject 
may not be assigned to ano ther subject. Subjects who withdraw will not be replaced.
10.3. Withdrawal From the Use of Samples in Future Research
The subject may  withdraw consent for use of samples for future research (refer to Section 16.2.5 , 
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will be 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
62
Approved , Date: 17 July 2020destroy ed after they are no longer needed for the clinical study . Details of the sample retention for 
research are presented in the main I CF.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is o utlined 
below. Specific details will be provided in the statistical analy sis plan (SAP) .
11.1. Analysis Populations
Enrolled Population : All subjects who are enrolled into the study. This population will be used for 
exploring efficacy /anti-tumor activity ,subjec t disposition and biomarker analy ses.
Primary  Efficacy  Population: All subjects who received at least 1 dose of study  drug, had either 
biallelic BRCA (BRCA1 or BRCA2 )per the sponsor -validated blood -or tissue -based assay , or 
germline pathogenic BRCA ( BRCA1 or BRCA2) mutation . 
Safety  Population: All subjects who received at least 1 dose of stud y dru g. This population will be 
used for evaluating safety and treatment compliance.
Patient- report Outcomes Population (PRO) :All subjects who completed the baseline assessment 
and at least [ADDRESS_1044546]-P, or EQ- 5D-5L questionnaires.
Population Pharmacokinetics Populations (PK) :All subjects who received 1dose of study  drug 
and have at least [ADDRESS_1044547]- treatment.
11.2. Sample Size Determination
For the primary  objective with ORR endpoint in subjects with measurable mCRPC and 
DNA- repair anomalies in BRCA1 or BRCA2 , defined in Section 2.1, the null hypothesis that the 
ORR is ≤15% will be tested against the alternate hypothesis that the ORR is ≥32%. Efficacy  of 
niraparib will be declared if the lower bound of the 2-sided 95% exact CI for ORR is >15%.19With 
approximately  [ADDRESS_1044548] over 90% power such that the lower limit of the 95% CI for ORR
exceeds 16%. It is anticipated that the final analy sis for ORR will occur at approximatel y 
30 months (approximately [ADDRESS_1044549] enrolled).
For the secondary  objective with ORR endpoint in subjects with measurable mCRPC and 
DNA- repair anomalies inbiallelic non-BRCA (ATM, FANCA, PALB2, CHEK2, BRIP1, or 
HDAC2 ), the null hypothesis that the ORR is ≤15% will be tested against the alternate hypothesis 
that the ORR is ≥32%.With a 1-sided of 0.05 and power of 80%, up to45subjects with
measurable mCRPC and DNA- repair anomalies in non-BRCA (ATM, FANCA, PALB2, CHEK2, 
BRIP1, or HDAC2 )are to be enrolled based on Simon’s two-stage design.14At end of Stage 1, 
approximately  14subjects will be evaluated for ORR after at least [ADDRESS_1044550] stage. Otherwise, enrollment may proceed to the second stage 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
63
Approved , Date: 17 July 2020with a total of 45 subjects combined for the 2 stages, and the null hypothesis will be rejected if 
10or more responses are observed.
Assuming the historical CTC response rate (CTC RR) of  
and the target CTC RR of 40%, at least 60 subjects with non-measurable 
disease will be required to provide a lower bound of the 2 -sided 95% CI greater than 20%, wi th a 
probability  of 0.9.
11.3. Efficacy  Analyses
ORR in subjects with measurable mCRPC and DNA- repair anomalies ineither biallelic BRCA 
(BRCA1 or BRCA2 )or germline BRCA (BRCA1 or BRCA2), and ORR in subjects with 
measurable mCRPC and DNA -repair anomalies in biallelic non-BRCA ( ATM, FANCA, PALB2, 
CHEK2, BRIP1, or HDAC2 ), as defined in Section 2.1, will be calculated, and its 2-sided 95% 
exact CI will also be presented. For the calculation of ORR, subjects in the Primary  Efficacy
Population who discontinue treatment prior to any efficac y assessments will be considered as non-
responders. The final analy sis for ORR in subjects with measurable mCRPC and DNA- repair 
anomalies in BRCA1 or BRCA2 will be performed approximately  6months after the last subject 
with measurable disease and DNA- repair anomalies in BRCA1 or BRCA2 receives his first dose 
of study  medication.
The analy sis for CTC RR will be tabulated andits 2-sided 95% exact CI will also be presented. 
The distribution of the time -to-event endpoints will be described using the Kaplan -Meier method. 
Additional details will be provided in the SAP.
Anti- tumor activity , such as PSA response, CTC conversion, composite response rate, will be 
analyzed based on subgroups of the enrolled population of biallelic, monoallelic, and 
indeterminant (local test results only ) biomarker status. Additional details will be provided in the 
SAP.
11.4. Pharmacokinetic A nalyses
Individual niraparib (and its metabolite, M1) concentration -time data will be listed and 
summarized by  [CONTACT_762446]. I n addition, a population PK analysis of plasma concentration -time 
data of niraparib will be performed using nonlinear mixed -effects modeling to estimate oral 
clearance (CL/F) and oral volume of distribution (V/F). Other PK parameters may be evaluated as 
appropriate. Subject characteristics of interest (eg, body  weight, age, renal function) may be 
evaluated as potential covariates affecting PK parameters. Details of the population PK analysis 
results will be presented in a separate report.
11.5. Pharmacody namic Analy ses
Pharmacod ynamics analyses were removed per Amendment 3.
11.6. Biomarker A nalyses
The concordance of DNA -repair anomalies in genes among tumor DNA and plasma ctDNA results 
may be evaluated. 
CCI
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
64
Approved , Date: 17 July 2020The association of biomarker -positivity  with clinical response or time -to-event endpoints may  be 
assessed using appropriate statistical methods, (such as analysis of variance, categorical, or 
survival models), depending on the endpoints. Correlation of baseline biomarker expression levels 
with clinical response or relevant time to-event endpoints may be performed to identify  responsive 
(or resistant) subgroups. Appropriate details of these exploratory  analyses will be included in the 
biomarker SAP .
11.7. Patient -reported Outcome A nalyses
BPI-SF, FACT -P, and EQ -5D- 5L will be summarized over time using descriptive statistics. Time 
to degradation (threshold to be defined in the SAP) may be analyzed using the Kaplan -Meier 
method.
11.8. Pharmacokinetic/Pharmacody namic A nalyses
The relationship between measure of exposure (eg, derived AUC or predose concentrations) and 
key efficacy  (eg, RR, PSA) and safety  parameters, will be explored graphically , as data allow. In 
addition, the relationship may be characterized using an appropriate PK/pharmacod ynamics or 
logistic regression model. Details will be provided in a separate report.
11.9. Medical Resource Utilization A nalyses
The anal ysis will be prepared separately  and will not be a part of the Clinical Study  Report.
11.10. Interim A nalysis
Refer to the SAP for an y interim analy ses to be conducted.
11.11. Safety  Analyses
Subjects who receive at least 1 dose of study  drug will be analyzed for safet y. The safet y 
parameters to be evaluated are theincidence, intensity , and type of AEs, vital signs measurements, 
ECGs, physical examination (abnormalities will be recorded as AEs) , and clinical laboratory 
results.
Adverse Events
The verbatim terms used in the eCRF by [CONTACT_43760] (MedDRA) and will be graded according to the 
National Cancer Institute -Common Terminology  Criteria for Adverse Event s (NCI -CTCAE), 
version 4.03 or later. Treatment- emergent AEs (TEAEs) are those events that occur on or worsen 
after first dose of study drug through [ADDRESS_1044551] narratives may be provided, as appropriate, for those subjects who die, who discontinue 
treatment due to an AE, or who experience a severe AE or an SAE.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
65
Approved , Date: [ADDRESS_1044552] toxicity  grade during treatment will 
be presented, according to NCI-CTCAE (version 4.03 or later). A listing of subjects with any 
markedl y abnormal laboratory results will also be provided.
Electrocardiogram (ECG)
ECG data will be summarized by [CONTACT_105292] , as appropriate. Descriptive statistics will be 
calculated at baseline and for observed values and changes from baseline at each scheduled 
timepoint. The last available predose ECG will be used as baseline. Frequency  tabulations of the 
abnormalities will be made.
Vital Signs
Descriptive statistics of pulse/heart rate, blood pressure, and temperature values and changes from 
baseline will be summarized at each scheduled timepoint. The percentage of subjects with values 
beyond clinicall y important limits will be summarized.
11.12. Data Review  Committee
A DRC will be established for this study  to review the planned analysis (see Section 11.10 ) and 
ongoing safet y data. The DRC may include individuals both internal and external to the sponsor 
who are knowledgeable in the disease area. The DRC responsibilities, authorities, and procedures 
will be documented in a separate document.
12. ADVERSE EVENT REPORT ING
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
[CONTACT_23824]. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies condu cted by [CONTACT_43765].
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
66
Approved , Date: [ADDRESS_1044553] administered a medic inal 
(investigational or non-investigational) product. An AE does not necessarily  have a causal 
relationship with the treatment. An AE can therefore be any unfavorable and unintended sign 
(including an abnormal finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational or non-investigational) product, whether or not related to that medicinal 
(investigational or non-investigational) product. (Definition per International Conference on 
Harmonisation [I CH]).
This includes any occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects AEs 1) starting with the signing of the prescreening ICF for AEs related 
to blood and recent tumor tissue collection during the Prescreening Phase, and 2) starting with the 
signing of the main study ICF for all other AEs (refer to Section 12.3.[ADDRESS_1044554] AE recording).
Serious Adverse Event
An SAE based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for 
Human Use is an y untoward medical occurrence that at any  dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe)
Requires inpatient hospi[INVESTIGATOR_159070]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical andscientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be immediatel y 
life-threatening or result in death or hospi[INVESTIGATOR_66816]. These should 
usually  be considered serious.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
67
Approved , Date: 17 July 2020Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AE is considered unlisted if the nature or severity  is not consistent with the applicable product 
reference safet y information. For niraparib , the expectedness of an AE will be determined by 
[CONTACT_83408]'s Brochure.
Adverse Event Associated With the Use of the Drug
An AE is considered associated with the use of the drug if the attribution is possible, probable, or 
very likely  by [CONTACT_23826] 12.1.2 , Attribution Definitions.
12.1.2. Attribution Definitions
Not Related
An AE that is not related to the use of the drug.
Doubtful
An AE for which an alternative explanation is more likely , eg,concomitant drug(s), concomitant 
disease(s), or t he relationship in time suggests that a causal relationship is unlikely .
Possible
An AE that might be due to the use of the drug. An alternative explanation, eg,concomitant 
drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, 
the causal relationship cannot be excluded.
Probable
An AE that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed b y dechallenge). An alternative explanation is less likel y, eg, concomitant dr ug(s), 
concomitant disease(s).
Very Likely
An AE that is listed as a possible adverse reaction and cannot be reasonably  explained by [CONTACT_43767], eg, concomitant drug(s), concomitant disease(s). The relationship in time 
is very  suggestive (e g,it is confirmed by  [CONTACT_35719]).
12.1.3. Severity Criteria
An assessment of severity  grade will be made using the NCI -CTCAE (version 4.03 or later). Any 
AE not listed in the NCI -CTCAE will be graded according to the investigator’s clinical judgm ent 
using the standard grades as follows:
Grade 1 (Mild) : Awareness of symptoms that are easily tolerated, causing minimal discomfort 
and not interfering with every day activities.
Grade 2 (Moderate) : Sufficient discomfort is present to cause interference w ith normal activity .
Grade 3 (Severe) : Extreme distress, causing significant impairment of functioning or 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
68
Approved , Date: 17 July 2020incapacitation. Prevents normal every day activities.
Grade 4, Life- threatening: Urgent intervention indicated.
Grade 5, Death : Death.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drug that may require expedited reporting orsafet y 
evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor stud y drug
Inadvertent or accidental exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to the 
sponsor study  drug, eg, name [CONTACT_2976])
Special reporting situations should be recorded in the eCRF. Any special reporting situation that 
meets the criteria of an SAE should be recorded on the serious AE page of the eCRF.
12.3. Proce dures
12.3.1. All Adverse Events
All AEs and special reporting situations, whether serious or non- serious, will be reported from the 
time a signed and dated main study  ICF is obtained until completion of the subject's last study -
related procedure, which may includ e contact [CONTACT_20687] -up of safety . SAEs, including those 
spontaneously  reported to the investigator through [ADDRESS_1044555] 
be reported using the Serious Adverse Event Form. In addition, SAEs related to blood or recent 
tumor tissue collection procedures, as well as death from any cause, during the Prescreening Phase 
will also be reported from the time the prescreening ICF is signed until 30days after the 
procedure/s occur . These Prescreening Phase SAEs should only be reporte d to the sponsor ’s 
pharmacovigilance team using paper SAE forms and should not be entered into the eCRF . For an y 
of these subjects who subsequently  sign the main ICF, the events need to be entered into the eCRF . 
The sponsor will evaluate an y safety informa tion that is spontaneously  reported b y an investigator  
beyond the time frame specified in the protocol.
All events that meet the definition of a SAE will be reported as SAEs, regardless of whether they 
are protocol -specific assessments. Anticipated events will be recorded and reported as described 
inAttachment 6.
All AEs, regardless of seriousness, severit y, or presumed relationship to study  drug, must be 
recorded using medical terminology  in the source document and the eCRF. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common e tiology  (eg,cough, 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
69
Approved , Date: 17 July 2020runny  nose, sneezing, sore throat, and head congestion should be reported as "upper respi[INVESTIGATOR_28945]"). Investigators must record in the eCRF their opi[INVESTIGATOR_762418] y. All measures requir ed for AE management must be recorded in the source 
document and reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate reporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute where 
required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) associated with the use of 
the study  drug. For anticipated events reported as individual SAEs the sponsor will make a 
determination of relatedness in addition to, and independent of, the investigator ’s assessment. The 
sponsor will periodically  evaluate the accumulating data and, when there is sufficient evidence and 
the sponsor has determined there is a reasonable possibility  that the drug caused a serious 
anticipated event, will submit a safety report in narrative format to the investigators (and the head 
of the institute). The investigator (or sponsor where required) must report these events to the 
appropriate Independent Ethics Committee/I nstitutional Review Board (IEC/I RB) that approved 
the protocol unless otherwise required and documented b y the IEC/IRB.
For all studies with an outpatient phase, including open -label studies, the subject must be provided 
with a "wallet (study )card" and instructed to carry  this card with them for the duration of the study  
indicating the following:
Study  number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] 24- hour contact [CONTACT_762447]
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_1044556] telephone number (for medical staf f onl y)
Site number
Subject number
12.3.2. Serious A dverse Events
All SAEs occurring during the study  must be reported to the appropriate sponsor contact [CONTACT_67816] -site personnel within [ADDRESS_1044557] be completed and signed by  a phy sician from the study  site, and transmitted to 
the sponsor within 24 hours. The initial and follow -up reports of an SAE should be made by 
[CONTACT_6972] (fax) .
All SAEs that have not resolved by [CONTACT_2054] , or that have not resolved upon 
discontinuation of the subject's participation in the study , must be followe d until any of the 
following occurs:
The event resolves
The event stabilizes
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
70
Approved , Date: 17 July 2020The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the stud y dru g or to factors unrelated to stud y 
conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration of 
due diligence with follow -up efforts)
Suspected transmission of an inf ectious agent by  a medicinal product will be reported as an SAE. 
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the 
course of a subject's participation in a study  must be reported as an SAE , except hospi[INVESTIGATOR_762419]:
Surgery  or procedure planned before entry  into the study  (must be documented in the eCRF).
Disease progression should not be recorded as an AE or SAE term; instead, signs and symptoms 
of clinical sequelae resulting from disease progr ession/lack of efficacy  will be reported if they 
fulfill the SAE definition (refer to Section 12.1.1 , Adverse Event Definitions and Classifications).
During the Follow -up Phase of the study , deaths regardless of causality  will be reported in the 
eCRF. SAEs, including those spontaneousl y reported to the investigator within 30days after the 
last dose of study  drug, must be reported using the Serious Adverse Event Form. SAEs that occur 
after [ADDRESS_1044558] of the study  drug on sperm is unknown, PARP inhibitors disrupt DNA -repair of 
dividing cells and niraparib was observed to be genotoxic in in vitro studies.12Therefore, pregnancies 
in partners of male subjects included in the study should be reported by [CONTACT_114093] -site personnel 
within 24 hours of their knowledge of the event using the appropriate pregnancy  notification form. 
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required.
12.3.4. Disease Progres sion and Death
Progression of disease should not be considered nor should be reported as an adverse event (or 
serious adverse event). However, signs and symptoms of disease progression or of clinical 
sequelae resulting from disease progression/lack of efficacy that are determined by [CONTACT_762448] (refer to 
Section 12Adverse Event Reporting and Section [ADDRESS_1044559] Quality  Complaint Handling).
As OS is an endpoint of the study , all subjects must be followed for survival until death and 
information relating to a subject’s death (eg, date of death and primary  cause of death) should be 
recorded. Fatal events (regardless of relationship to study  drug) should be reported as SAEs for 
subjects until [ADDRESS_1044560] dose of study  drug will not be reported as SAEs and will be captured on the 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
71
Approved , Date: [ADDRESS_1044561] dose of study drug should include an AE term for the 
cause of death (if known).
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_476007] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, including its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated b y regulatory  agencies worldwide. The sponsor has estab lished 
procedures in conformity with regulatory requirements worldwide to ensure appropriate reporting 
of PQC information; all studies conducted by [CONTACT_43765].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_1044562] report the PQC to the sponsor according to the SAE reporting timeline s (refer to 
Section 12.3.2 , Serious Adverse Events). A sample of the suspected product should be maintained 
for further investigation if requested b y the sponsor.
13.2. Contact[CONTACT_23834] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug
Theniraparib capsule supplied for this study  contains 100 mg of niraparib . It will be manufactured 
and provided under the responsibility  of the sponsor .Refer to the Investigator's Brochure for a list 
of excipi[INVESTIGATOR_840].12
14.2. Packaging
Niraparib 100 mg capsules will be packaged in high-density  polyethylene bottles with 
child- resistant closures.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
72
Approved , Date: [ADDRESS_1044563] adverse effects on a fetus in utero. Caregivers should handle niraparib with 
protection (eg, gloves). It is not known whether niraparib is present in, or has transient effects on 
the composition of semen. To avoid risk of drug exposure through the ejaculate (even men with 
vasectomies), subjects must use a condom during sexual activity  while on study  drug and for [ADDRESS_1044564] dose of study  drug. Refer to the pharmacy  manual/study  
site investigational product and procedures manual for additional guidance on study  drug 
preparation, handling, and storage.
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study .The dispensing of study  drug to the subject, and the return 
of study  drug from the subject, must be documented on the drug accountability  form. Subjects, or 
their legally  acceptable representatives where applicable, must be instructed to return all origin al 
containers, whether empty or containing stud y drug. All stud y drug will be stored and disposed of 
according to the sponsor's instructions. Study -site personnel must not combine contents of the 
study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug, and study  drug returned by [CONTACT_423], must be 
availa ble for verification by [CONTACT_456]'s study -site monitor during on -site monitoring visits. The 
return to the sponsor of unused study  drug, or used returned study  drug for destruction, will be 
documented on the drug return form. When the study  site is an authorized destruction unit and 
study  drug supplies are destroy ed on -site, this must also be documented on the drug return form.
Study  drug should be dispensed under the supervision of the investigator or a qualified member of 
the study -site personnel, or bya hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied only to 
subjects participating in the study . Returned study drug must not be dispensed again, even to the 
same subject. Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The 
investigator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study  sites agreed upon with the sponsor.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
73
Approved , Date: 17 July 202015. STUDY -SPECIFIC MATER IALS
The investigator will be provided with the following supplies:
 Investigator's Brochure  PRO questionnaires
 Pharmacy manual/study -site investigational 
product and procedures manual RECIST 1.1
 Electronic data capture (eDC) Manual  Sample prescreening ICF
 Laboratory manual  Sample main study ICF
 Recruitment materials
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
This is an open -label study  to evaluate the efficacy  and safety  of niraparib in men with mCRPC 
and DNA- repair anomalies. While niraparib is an investigational PARP inhibitor, responses to a 
drug with a similar mechanism of action (olaparib; see Section 1.1) have been observed in men 
with mCRPC. Subjects with DNA- repair anomalies exhibited better response rates compared to 
subjects without DNA- repair anomalies. Given these promising clinical data, the benefit of 
treatment with niraparib in men with mCRPC and prospectivel y selected DNA- repair anomalies 
outweighs the potential risks involved.
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential AEs of the study, and provid e their consent voluntaril y will be enrolled.
All participating subjects will receive full supportive care and will be followed closely  for efficacy  
and safet y throughout the study . As objective response is the primary  endpoint, scheduled imaging 
is incorporated into the protocol. The timing of imaging is designed to evaluate response and 
capture progression events and allow the clinical investigator to make timely  treatment decisions, 
yet balancing this with preventing subject overexposure to radiation. Th e frequency of scanning is 
consistent with requirements to assess rPFS by [CONTACT_43877]3 criteria.20A DRC will be commissioned 
to review the efficacy and s afety of the treatment on an ongoing basis and make recommendations 
as to the future conduct of the study . 
As with all clinical and PK studies, there are risks associated with venipuncture and multiple blood 
sample collection. To avoid multiple venipunctu res, the use of intravenous indwelling catheters is 
permitted in this study. The blood sample collection scheme was designed to collect the minimum 
number of blood samples that can determine the efficacy, safety, PK, and biomarker requirements 
of the study . Note that the total volume of blood to be collected is an estimate (see Section 
9.1.1 ); 
the actual amount may  vary depending on laboratory standa rd procedures. The volume of blood to 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
74
Approved , Date: 17 July 2020be drawn is considered customary  and acceptable for subjects participating in an oncology  study 
and is deemed reasonable over the time frame of the study , based upon the standards of the WHO.23
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
GCP  is an international ethical and scientific quality  standard for designing, conducting, recording, 
and reporting studies that involve the participation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety , and 
well-being of study  subjects are 
protected, consistent with the principles that originated in the Declaration of Helsinki, and that the 
study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the IEC/I RB 
with current and complete copi[INVESTIGATOR_23747] (as require d by [CONTACT_427]):
Final protocol and, if applicable, amendments
Sponsor -approved ICF (and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as documented 
by [CONTACT_6179]/IRB)
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only af ter the IEC/IRB has given full approval of the final protocol, 
amendments (if any, excluding the ones that are purely  administrative, with no consequences for 
subjects, data or study  conduct, unless required locally ), the ICF, applicable recruiting materia ls, 
and subject compensation programs, and the sponsor has received a copy of this approval. This 
approval letter must be dated and must clearly  identify  the IEC/I RB and the documents being 
approved.
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
75
Approved , Date: 17 July 2020Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision( s) to I CF and any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the Investigator's Brochure and amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/I RB
(atleast annually )
Reports of AEs that are serious, unlisted/unexpected, and a ssociated with the study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Report and Line Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct) , the amendment and applicable ICF revisions 
must be submitted promptly to the IEC/IRB for review and approval before implementation of the 
change(s). At least once a year,the IEC/IRB will be asked to review and reapprove this study , 
where required. At the end of the study , the investigator (or sponsor where required) will notify  
the IEC/I RB about the study  completion (if applicable, the notification will be submitted throu gh 
the head of investigational institution).
16.2.3. Informed Consent
Each subject must provide consent according to local requirements after the nature of the study 
has been fully explained ; consenting will include remote/virtual consent or written consent . 
Conse ntmust be given before performance of any study-related activity . The ICF(s) that is/are 
used must be approved by [CONTACT_8135]/I RB and be in a language 
that the subject can read and understand. The informed consent should be in accordance with 
principles that originated in the Declaration of Helsinki, current ICH and GCP guidelines, 
applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study -site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary and that they may withdraw consent 
to participate at an y time. They  will be informed that choosing not to participate will not affect the 
care the subject will receive for the treatment of their disease. Subjects will be told that alternative 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
76
Approved , Date: [ADDRESS_1044565], to the extent permitted by [CONTACT_6983](s) or regulations. By [CONTACT_762449] , which includes permission to obtain information about his 
survival status and agrees to allow his study  physician to recontact [CONTACT_762450] -related treatments, if 
needed.
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. After 
this explanation and before entry  into the study , consent should be appropriately  recorded by [CONTACT_460475]'s personally  dated signature. After having obtained the consent, a copy of the ICF 
must be given to the subject.
16.2.4. Privacy of Personal Data
The collection and processing of personal data from s ubjects enrolled in this study will be limited 
to those data that are necessary  to fulfill the objectives of the study .
These data must be collected and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data priva cy protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized disclosures 
or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. 
Sponso r personnel whose responsibilities require access to personal data agree to keep the identity 
of subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator/in stitution to allow direct access to his original medical 
records (source data/documents) for study -related monitoring, audit, IEC/I RB review, and 
regulatory  inspection. This consent also addresses the transfer of the data to other entities and to 
other countries.
The subject has the right to request through the investigator access to his personal data and the 
right to request rectification of an y data that are not correct or complete. Reasonable steps will be 
taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  DNA, biomarker, and pharmacokinetics research is not conducted under standards 
appropriate for the return of data to subjects. In add ition, the sponsor cannot make decisions as to 
the significance of any findings resulting from exploratory  research. Therefore, exploratory  
research data will not be returned to subjects or investigators, unless required by [CONTACT_117201]. Privac y and confidentiality  of data generated in the future on stored samples will be 
protected b y the same standards applicable to all other clinical data.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
77
Approved , Date: 17 July 202016.2.5. Long -Term Retention of Samples for A dditional Future Research
Samples collected in this study  may be stor ed for up to 15 y ears (or according to local regulations) 
for additional research. Samples will only  be used to understand niraparib , to understand prostate 
cancer in patients with DNA- repair anomalies, to understand differential drug responders, and to 
develop tests/assay s related to niraparib and prostate cancer in patients with DNA- repair 
anomalies. The research may  begin at any  time during the study  or the post -study  storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research.
16.2.6. Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwi se help 
ensure access to the developed product if the need for the product persists, unless explicitly  
addressed as a specific ethical consideration in Section 16.1, Study -Specific Design 
Considerations.
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify this protocol without a formal amendment b y 
the sponsor. All protocol amendments must be issued b y the sponsor, and signed and dated b y the 
investigator. Protocol amendments must not be implemented without prior IEC/IRB approval, or 
when the relevant competent authority  has raised any grounds for non-acceptance, except when 
necessary  to eliminate immedi ate hazards to the subjects, in which case the amendment must be 
promptly  submitted to the IEC/IRB and relevant competent authorit y. Documentation of 
amendment approval b y the investigator and IEC/IRB must be provided to the sponsor. When the 
change(s) involves only logistic or administrative aspects of the study , the IEC/I RB (where 
required) onl y needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_90814](s), which will be provided as a separate document. Except 
in emergency  situations, this contact [CONTACT_393404]. In all cases, contact [CONTACT_90816]. The data recorded in the eCRF and source 
documents will reflect any departure from the protocol, and the source documents will describe 
this departure and the circumstances requiring it.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
78
Approved , Date: 17 July 202017.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory  
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study  site:
Protocol and amen dment(s), if any , signed and dated by  [CONTACT_458].
A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) b y the chairman or authorized designee.
Name [CONTACT_23875]/IRB, inc luding a current list of the I EC/I RB members and their 
function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, from 
the IEC/IRB, a gene ral statement may be substituted for this list. If an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the vote/opi[INVESTIGATOR_66821] .
Regulatory  authority  approval or notification, if applicable.
Signed and dated statement of investigator (eg, Form FDA 1572), if applicable.
Documentation of investigator qualifications (eg, curriculum vitae).
Completed investigator financial disclosure form from the principal investigator, where 
required.
Signed and dated clinical trial agreement, which includes the financial agreement.
Any other documentation required by  [CONTACT_427].
The following documents must be provided to the spon sor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators.
Documentation of subinvestigator qualifications (eg, curriculum vitae).
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable.
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
79
Approved , Date: [ADDRESS_1044566] be available for the following to confirm data collected 
in the eCRF: subject identification, eligibility , and study  identification; study  discussion and date 
of signed informed consent; dates of visits; results of safet y and efficacy  parameters as required 
by [CONTACT_760]; record of all AEs and follow -up of AEs; concomitant medication; drug 
receipt/dispensing/return records; study  drug administration information ; paper PROs; and date of 
study  completion and reason for earl y discontinuation of study  drug or withdrawal from the study, 
if applicable. In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  and source data collec tion methods will be 
reviewed with the investigator before the study and will be described in the monitoring guidelines 
(or other equivalent document).
The minimum source documentation requirements for Section 4.2, Inclusion Criteria and 
Section 4.3, Exclusion Criteria that specify a need for documented medical history  are as follows:
Referral letter from treating ph ysician, or
Complete history  of medical notes at the site
Discharge summaries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_170190] (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospi[INVESTIGATOR_23749] (eg, electronic source documents) as well as the 
clinical study -specific data fields as determined by [CONTACT_760]. This data is electronically 
extracted for use b y the sponsor. If the electronic source s ystem is utilized, references made to the 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
80
Approved , Date: [ADDRESS_1044567]'s source documents. Data must be entered into the 
eCRF in English. The eCRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be completed 
by [CONTACT_762451].
If necessary , queries will be generated in the eDC tool. If corrections to an e CRF are needed after 
the initial entry  into the eCRF , this can be done in either of the following way s:
Investigator and study -site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]).
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_70449] -
site personnel.
17.6. Data Quality  Assurance/Qua lity Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -site personnel before the study , perio dic monitoring visits by [CONTACT_456], and direct 
transmission of clinical laboratory  data from a central laboratory  into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples.
Guidelines for case report form completion will be provided and reviewed with study -site 
personnel before the start of the study .The sponsor will review the eCRF for accuracy  and 
completeness during on-site monitoring visits and after transmission to the sponsor; any
discrepancies will be resolved with the investigator or designee, as appropriate. After upload of 
the data into the study database they will be verified for accuracy  and consistency  with the data 
sources.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
81
Approved , Date: [ADDRESS_1044568] Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all eCRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in I CH/GCP Section 8, Essential Documents for the Conduct of a Clinical 
Trial, and all study  documents as specified by [CONTACT_23859](s). The 
investigator/institution will take measures to prevent accidental or premature destruction of these 
documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing applications 
in an I CH region or until at least [ADDRESS_1044569]. These documents will be retained for a longer period 
if required by [CONTACT_66891]. It is the 
responsibility  of the sponsor to inform the investigator/institution as to when these documents no 
longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will accept 
the responsibility . The sponsor must be notified in writing of the name [CONTACT_66903]. Under no circumstance shall the investigator relocate or dispose of any study documents 
before having obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator/institution must permit access to such reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study -site visit log that will be kept at the study -site. The first 
post-initiation visit will be made as soon as possible after enrollment has begun. At these visits, 
the monitor will compare the data entered into the eCRF with the source documents 
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records). The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
eCRF are known to the sponsor and study -site personnel and are accessible for verification by [CONTACT_66886] -site contact. If electronic records are maintained at the study  site, the method of 
verification must be discussed with the study -site personnel.
Direct access to source documents (medical records) must be allowed for the purpose of verifying 
that the recorded data are consistent with the original source data. Findings from this review will 
be discussed with the study -site personnel. The sponsor expects that, during monitoring visits, the 
relevant study -site personnel will be available, the source documents will be accessible, and a 
suitable environment will be provided for review of study -related documents. The monitor will 
meet with the inves tigator on a regular basis during the study to provide feedback on the study
conduct.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
82
Approved , Date: 17 July 202017.9. Study Completion/Termination
17.9.1. Study Completion/End of Study
The study  is considered completed with the last study assessment for the last subject participating 
in the study . The final data from the study  site will be sent to the sponsor (ordesignee) after 
completion of the final subject assessment at that study  site, in the time frame specified in the 
clinical trial agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study  site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study  sites will be closed upon study  completion. A 
study  site is considered closed when all required documents and study  supplies have been collected 
and a stud y-site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of a study  site by [CONTACT_66892]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor' s clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study
records, including source documents, for inspection. Subject privacy  must, however, be respected. 
The investigator and study -site personnel are responsible for being present and available for 
consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_66893].
Similar auditing procedures may also be conducted by [CONTACT_23865], either as part 
of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission . The investigator should immediately  notify  the sponsor if he or she has 
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding niraparib or the sponsor's 
operations (eg,patent application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_43787], and an y data,including exploratory  biomarker research data, generated as a 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
83
Approved , Date: 17 July 2020result of this study , areconsidered confidential and remain the sole property  of the sponsor. The 
investigator agrees to maintain this information in confidence and use this information only to 
accomplish this study , and will not use it for other purposes without the sponsor's prior written 
consent.
The investigator understands that the information developed in the study will be used by [CONTACT_762452] o f niraparib , and thus may  be disclosed as 
required to other clinical investigators or regulatory  agencies. To permit the information derived 
from the clinical studies to be used, the investigator is obligated to provide the sponsor with all 
data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_66896]. Recruitment 
performance or specific expertise related tothe nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator [INVESTIGATOR_25810] . Results of exploratory 
biomarker analyses performed after the Clinical Study  Report has been issued will be reported in 
a separa te report and will not require a revision of the Clinical Study  Report. Study  subject 
identifiers will not be used in publication of results. Any work created in connection with 
performance of the study  and contained in the data that can benefit from copyright protection 
(except any publication by [CONTACT_40999]) shall be the propert y of the 
sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal
Editors guidelines, the sponsor shall have the right to publish such primary (multicenter) data and 
information without approval from the investigator. The investigator has the right to publish study 
site-specific data after the primary  data are published . If an investigator wishes to publish 
information from the study ,a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], the investigator will withhold such publication for up to an additional 60days to allow for 
filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with the investigator. The sponsor will 
not mandate modifications to scientific content and does not have the right to suppress information.
Formulticenter stud y designs and substud yapproaches, secondary  results generall y should not be 
published before the primary  endpoints of a study  have been published. Similarly , investigators 
will recognize the integrity  of a multicenter study by [CONTACT_369046], within 18months after the study  end date, orthe sponsor confirms there 
will be no multicenter study publication. Authorship of publications resulting from this study  will 
be based on the guidelines on authorship, such as those described in the ICMJE Recommendations 
for the Conduct, Reporting, Editi ng and Publication of Scholarl y Work in Medical Journals, which 
state that the named authors must have made a significant contribution to the conception or design 
of the work; or the acquisition, analy sis, or interpretation of the data for the work; and dr afted the 
work or revised it critically  for important intellectual content; and given final approval of the 
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
84
Approved , Date: 17 July 2020version to be published; and agreed to be accountable for all aspects of the work in ensuring that 
questions related to the accuracy or integrity of any part of the work are appropriatel y investigated 
and resolved.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as required 
by [CONTACT_2371].The disclosure of the final study  results will be performed after the end of study  in order 
to ensure the statistical analy ses are relevant.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
85
Approved , Date: 17 July 2020REFERENCES
1. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment 
of cancer s deficient in DNA double -strand break repair. J Clin Oncol. 2008;26(22):3785 -3790.
2. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2 -deficient tumours with inhibitors of 
poly(ADPribose) polymerase. Nature. 2005 Apr 14;434(7035):913 -917.
3. Buonerba C, Federico P, D'Aniello C, et al. Phase II trial of cisplatin plus prednisone in docetaxel -refractory 
castration -resistant prostate cancer patients. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455 -1461.
4. Drake CG, Sharma P, Gerritsen W. Metastatic c astration -resistant prostate cancer: new therapi[INVESTIGATOR_014], novel 
combination strategies and implications for immunotherapy. Oncogene. [ADDRESS_1044570] 23;33(43):5053 -5064.
5. Droz JP, Muracciole X, Mottet N, et al. Phase II study of oxaliplatin versus oxaliplatin combined w ith 
infusional 5 -fluorouracil in hormone refractory metastatic prostate cancer patients. Ann Oncol. 2003 
Aug;14(8):1291 -1298.
6. Eisenhauer EA, Therasse P, Bogaerts, et al. New  response evaluation criteria in solid tumours: Revised 
RECIST guideline (version 1 .1). Eur J Cancer. 2009;45:[ADDRESS_1044571] in BRCA mutant cells as a therapeutic 
strategy. Nature. 2005;434(7035):917 -921.
8. FDA: Drug Development and Drug Interactions: Table of Substrates, Inhibi tors, and Inducers. Available at: 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/u
cm093664 htm. Accessed [ADDRESS_1044572], et al. The mutational landscape of lethal castration -resistant prostate 
cancer. Nature. 2012;487: 239 –243.
10. Gupta E, Guthrie T, Tan W. Changing paradigms in management of metastatic Castration Resistant Prostate 
Cancer (mCRPC). BMC Urol. 2014 Jul 25;14:55.
11. Indiana University Department of Medicine: P450 Drug Interaction Table. 
http://medicine.iupui.edu/CLINPHARM/ddis/main -table.
12. Investigator’s Brochure: Niraparib. Tesaro, Inc.
13. Jones P, Wilcoxen K, Row ley M, Toniatti C. Niraparib: A Poly(ADP -ribose) Polymerase (PARP) Inhibitor for 
the Treatment of Tumors with Defective Homologous Recombination. J Med Chem. 2015 Apr 23;58(8):3302 -
3314.
14. Lavaud P, Gravis G, Foulon S, et al. Anticancer Activity and Tolerance of Treatments Received Beyond 
Progression in Men Treated Upfront with Androgen Deprivation Therapy With or W ithout Docetaxel for 
Metastatic Castrate -naïve Prostate Cancer in the GETUG- AFU 15 Phase 3 Trial. Eur Erol. 2018; 73 (5): 696 -
703. 
15. Lin Y, Shih WJ. Adaptive tw o-stage designs for single -arm phase IIA cancer clinical trials. Biometrics. 
2004;60(2):[ADDRESS_1044573] 29;373(18):[ADDRESS_1044574]. http://www.crediblemeds.org.
18. Robinson D, Van Allen EM, Wu YM, et al. Integrative clinical genomi cs of advanced prostate cancer. Cell. 
2015;161(5):1215 -1228.
19. Sartor O and Gillessen S. Treatment sequencing in metastatic castrate- resistant prostate cancer. Asian J Androl. 
2014 May -Jun;16(3):426 -431.
20. Scher HI, Morris MJ, Stadler WM, et al. Trial Design a nd Objectives for Castration -Resistant Prostate Cancer: 
Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 
Apr 20;34(12):1402 -1418.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
86
Approved , Date: 17 July 202021. Smith MR, De Bono JS, Sternberg CN, et al. Final analysis of COMET -1: Cabozantinib (Cabo) versus 
prednisone (Pred) in metastatic castration -resistant prostate cancer (mCRPC) patients (pts) previously treated 
with docetaxel (D) and abiraterone (A) and/or enzalutamide (E). J Clin Oncol 33. 2015 ASCO Genitourinary 
Cancer Sympos ium Abstracts (suppl 7, abstr 139). Available at: 
http://meeting.ascopubs.org/cgi/content/abstract/33/7_suppl/139?sid=33f6458c -01a9 -4463 -b904 -1b61ffb5fa06
22. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) 
classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 
2009;114(5):937 -951.
23. WHO technical report series 840 (1994): Requirements for the blood collection, processing, and quality control 
of blood, blood components, and plasma derivatives. Available at: 
http://www. who.int/bloodproducts/publications/WHO_TRS_840_A2.pdf . Accessed [ADDRESS_1044575] Characteristics 2017. Available at: 
https://www.medicines.org.uk/emc/product/8828. Accessed on: 15 November 2018.
25. Zejula®[LOCATION_002] Prescribing Information 2018. Available at: https://www.zejula.com/prescribing -
information. Accessed on: 15 November 2018.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
87
Approved , Date: 17 July 2020Attachment 1:Prostate Cancer Working Group 3 Criteria
Attachment removed per Amendment 3.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
88
Approved , Date: 17 July 2020Attachment 2:Summary of RECIST Criteria Version 1.1 with Integration of PCWG3 for Evaluation 
of Response
The following information was extracted from Section 3, Section 4, and Appendix I of the New Response 
Evaluation Criteria in Solid Tumors: revised RECIST guideline (version 1.1) authored by [CONTACT_221846] 
(2009).6
3. Measurability of tumor at baseline
3.1 Definitions
At baseline, tumor lesions/lymph nodes will be categorized measurable or non -measurable as follows:
3.1.1 Measurable
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the plane of 
measurement is to be recorded) with a minimum size of:
 [ADDRESS_1044576] scan (CT scan slice thickness no greater than 5 mm)
The following two methods of measure are not all owed in this protocol:
 10 mm caliper measurement by [CONTACT_461] (lesions which cannot be accurately measured with 
calipers should be recorded as non -measurable)
 [ADDRESS_1044577] X -ray
 Malignant lymph nodes: To be considered pathologically enlarged and meas urable, a lymph node must 
be [ADDRESS_1044578] scan (CT scan slice thickness recommended to be no 
greater than 5 mm ). At baseline and in follow -up, only the short axis will be measured and followed. 
See also ‘Baseline documentation of target and non-target lesions’ in section 4.[ADDRESS_1044579] 
guideline for information on lymph node measurement.
3.1.2 Non-measurable
All other lesions, including small lesions (longest diameter <10 mm or pathological lymph nodes with 10 
to <15 mm short axis) as well as truly non-measurable lesions. Lesions considered truly non-measurable 
include: leptomeningeal disease, ascites, pleural or pericardial effusion, inflammatory breast disease, 
lymphangitic involvement of skin or lung, and abdominal masses/a bdominal organomegaly identified by 
[CONTACT_87415].
3.2 Specifications by [CONTACT_12009]
3.2.1 Measurement of lesions
All m easurements should be recorded in metric notation, using calipers if clinically assessed. All baseline 
evaluations should be performed as close as possible to the treatment start and never more than 4 weeks 
before the beginning of the treatment.
3.2.2 Method of assessment
The same method of assessment and the same techni que should be used to characterize each identified and 
reported lesion at baseline and during follow -up. Imaging based evaluation should always be done rather 
than clinical examination.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
89
Approved , Date: 17 July [ZIP_CODE]. Tumor response evaluation
4.1 Assessment of overall tumor burden an d measurable disease
To assess objective response or future progression, it is necessary to estimate the overall tumor burden at 
baseline and use this as a comparator for subsequent measurements.
4.2 Baseline documentation of ‘target’ and ‘non -target’ lesi ons
When more than one measurable lesion is present at baseline all lesions up to a maximum of five lesions 
total (and a maximum of two lesions per organ) representative of all involved organs should be identified 
as target lesions and will be recorded andmeasured at baseline (this means in instances where patients have 
only one or two organ sites involved a maximum of two and four lesions respectively will be recorded). For 
evidence to support the selection of only five target lesions, see analyses on a large prospective database in 
the article by [CONTACT_150064]. (Reference #10 in Eisenhauer publication).
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in additi on should be those that lend themselves to reproducible 
repeated measurements . It may be the case that, on occasion, the largest lesion does not lend itself to 
reproducible measurement in which circumstance the next largest lesion, which can be measured 
reproducibly, should be selected.
Lymph nodes merit special mention since they are normal anatomical structures, which may be visible by 
[CONTACT_33490]. As noted in Section 3, pathological nodes which are defined as 
measurable and may be identified as target lesions must meet the criterion of a short axis of [ADDRESS_1044580] in which the image is obtained (for CT scan this is almost 
always the axial plane; for MRI the plane of acquisition may be axial, sagittal or coronal). The smaller of 
these measures is the short axis. For example, an abdominal node which is reported as being 20mm•30 mm 
has a short axis of 20 mm and qualifies as a malignant, measurable node. In this example, 20mm should 
be recorded as the node measurement (See also the example in Fig. 4 in Appendix II of the Eisenhauer 
reference). All other pathological nodes (those with short axis 10 mm but <15 mm) should be considered 
non-target lesions. Nodes that have a short axis <10 mm are considered non -pathological and shou ld not be 
recorded or followed.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target lesions will 
be calculated and reported as the baseline sum diameters . If lymph nodes are to be included in the sum, 
then as noted above, only the short axis is added into the sum. The baseline sum diameters will be used as 
reference to further characterize any objective tumor regression in the measurable dimension of the disease.
All other lesions (or sites of disease) includi ng patholog ical lymph nodes should be identified as non-target 
lesions and should also be recorded at baseline. Measurements are not required and these lesions should be 
followed as ‘present’, ‘absent’, or in rare cases ‘unequivocal progression’ (more details to follow). In 
addition, it is possible to record multiple non-target lesions involving the same organ as a single item on 
the case record form (e.g. ‘multiple enlarged pelvic lymph nodes’ or ‘multiple liver metastases’).
4.3 Response criteria
This section provides the definitions of the criteria used to determine objective tumor response for target 
lesions.
4.3.1 Evaluation of target lesions
Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether 
target or non- target) must have reduction in short axis to <10 mm.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
90
Approved , Date: 17 July 2020Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as 
reference the baseline sum diameters.
Progressive Disease: At least a 20% increase in the sum of diameters of target lesions, taking as reference 
the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the 
relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the 
appearance of one or more new lesions is also considered progression).
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for 
progressive disease, taking as reference the smallest sum diameters while on study.
4.3.[ADDRESS_1044581] the actual short axis 
measurement recorded (measured in the same anatom ical plane as the baseline examination), even if the 
nodes regress to below 10 mm on study. This means that when lymph nodes are included as target lesions, 
the ‘sum’ of lesions may not be zero even if complete response criteria are met, since a normal lym ph node 
is defined as having a short axis of <[ADDRESS_1044582] achieve a short axis <10 mm. For PR, SD and progressive disease, the actual short 
axis measurement of the nodes is to be included in the sum of target lesions.
Target lesions that become ‘too small to measure’ . While on study, all lesions (nodal and non-nodal) 
recorded atbaseline should have their actual measurements recorded at each subsequent evaluation, even 
when very small (eg 2 mm). However, sometimes lesions or lymph nodes which are recorded as target 
lesions at baseline become so faint on CT scan that the radiologi st may not feel comfortable assigning an 
exact measure and may report them as being ‘too small to measure’. When this occurs it is important that a 
value be recorded on the CRF. If it is the opi[INVESTIGATOR_26191], 
the measurement should be recorded as 0 mm. If the lesion is believed to be present and is faintly seen but 
too sm all to m easure, a default value of 5 mm should be assigned ( Note : It is less likely that this rule will 
be used for lymph nodes since they usually have a definable size when normal and are frequently 
surrounded by [CONTACT_12156]; however, if a lymph node is believed to be present and is 
faintly seen but too small to measure, a default value of 5 mm should be assigned in this circumstance as 
well). This default value is derived from the [ADDRESS_1044583] slice thickness (but should not be changed with 
varying CT slice thickness). The measurement of these lesions is potentially non-reproducible; therefore 
providing this default value wi ll prevent false responses or progressions based upon measurement error. To 
reiterate, however, if the radiologist is able to provide an actual measure, that should be recorded, even if it 
is below 5 mm.
Lesions that split or coalesce on treatment . When non-nodal lesions ‘fragment’, the longest diameters of 
the fragmented portions should be added together to calculate the target lesion sum. Similarly, as lesions 
coalesce, a plane between them may be maintained that would aid in obtaining maximal diameter 
measurements of each individual lesion. If the lesions have truly coalesced such that they are no longer 
separable, the vector of the longest diameter in this instance should be the maximal longest diameter for the 
‘coalesced lesion’.
4.3.3 Evaluation of non -target lesions
This section provides the definitions of the criteria used to determine the tum or response for the group of 
non-target lesions. While some non -target lesions may actually be measurable, they need not be measured 
and instead should be assess ed only qualitatively at the timepoints specified in the protocol.
Complete Response (CR): Disappearance of all non-target lesions and normalization of tumor marker 
level. All lymph nodes must be non- pathological in size (<10 mm short axis).
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
91
Approved , Date: 17 July 2020Non-CR/Non -progressive disease: Persistence of one or more non -target lesion(s) and/or maintenance of 
tumor marker level above the normal limits.
Progressive Disease: Unequivocal progression (see comments below) of existing non-target lesions. (Note: 
the appearance of one or more new lesions is also considered progression).
4.3.4 Special notes on assessment of progression of non -target disease
The concept of progression of non -target disease requires additional explanation as follows:
When the patient also has measurable disease . In this setting, to achieve ‘unequivocal progression’ on the 
basis of the non -target disease, there must be an overall level of substantial worsening in non -target disease 
such that, even in presence of SD or PR in target disease, the overall tumor burden has increased sufficiently 
to merit discontinuation of therapy. A modest ‘increase’ in the size of one or more non-target lesions is 
usually not sufficient to quality for unequivocal progression status. The designation of overall progression 
solely on the basis of change in non -target disease in the face of SD or PR of target disease will therefore 
be extremely rare.
When the patient has only non-measurable disease . This circumstance arises in some Phase studies when 
it is not a criterion of study entry to have measurable disease. The same general concepts apply here as 
noted above, however, in this instance there is no measurable disease assessment to factor into the 
interpretation of an increase in non-measurable disease burden. Because worsening in non-target disease 
cannot be easily quantified (by [CONTACT_108]: if all lesions are truly non-measurable) a useful test that can be 
applied when assessing patients for unequivocal progression is to consider if the increase in overall disease 
burden based on the change in non-measurable disease is comparable in magnitude to the increase that 
would be required to declare progressive disease for measurable disease: i.e. an increase in tumor burden 
representing an additional 73% increase in ‘volume’ (which isequivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from ‘trace’ to ‘large’, an increase 
in lymphangitic disease from localized to widespread, or may be described in protocols as ‘sufficient to
require a change in therapy.’ If ‘unequivocal progression’ is seen, the patient should be considered to have 
had overall progressive disease at that point. While it would be ideal to have objective criteria to apply to 
non-measurable disease, the very nat ure of that disease makes it impossible to do so, therefore the increase 
must be substantial.
4.3.5 New  lesions
The appearance of new malignant lesions denotes disease progression; therefore, some comments on 
detection of new lesions are important. There are no specific criteria for the identification of new 
radiographic lesions; however, the finding of a new lesion should be unequivocal: i.e. not attributable to 
differences in scanning technique, change in imaging modality or findings thought to represent something 
other than tumor (for example, some ‘new’ bone lesions may be simply healing or flare of pre-existing 
lesions). This is particularly important when the patient’s baseline lesions show partial or complete 
response. For example, necrosis of a liver lesion may be reported on a CT scan report as a ‘new’ cystic 
lesion, which it is not.
A lesion identified on a follow -up study in an anatomical location that was not scanned at baseline is 
considered a new lesion and will indicate disease progression. An example of this is the patient who has 
visceral disease at baseline and while on study has a CT or MRI brain ordered which reveals metastases. 
The patient’s brain metastases are considered to be evidence of progressive disease even if he/she did not 
have b rain imaging at baseline.
If a new lesion is equivocal, for example because of its small size, continued therapy and follow -up 
evaluation will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new 
lesion, then progre ssion should be declared using the date of the initial scan.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
92
Approved , Date: [ADDRESS_1044584] non -measurable (therefore non -target) disease only, the RECIST 1.1 
and PCWG3 timepoint response will be integr ated to determine the overall timepoint response.
4.4.2 Missing assessments and inevaluable designation
When no imaging/measurement is done at all at a particular timepoint, the patient is not evaluable (NE) at 
that timepoint. If only a subset of lesion me asurements are made at an assessment, usually the case is also 
considered NE at that timepoint, unless a convincing argument can be made that the contribution of the 
individual missing lesion(s) would not change the assigned timepoint response. This would be most likely 
to happen in the case of progressive disease. For example, if a patient had a baseline sum of [ADDRESS_1044585] overall response: all timepoints
The best overall response is the best response recorded from the start of the treatment until disease 
progression/recurrence (taking as reference for progressive disease the smallest measurements recorded 
since the treatment started). The patient's best response assignment will depend on the achievement of both 
measurement and confirmation criteria.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
93
Approved , Date: 17 July 2020Table 1: Overall Timepoint Response - Subjects with Target (+/ -Non-target) Disease +/ -Bone Disease
Target 
lesionsNon-target 
lesionsNew 
lesionsOverall 
RECIST v1.1 
response 
(nodal/visceral)Best overall response 
RECIST v1.1 when 
confirmation is 
requiredaOverall PCWG3 
response (bone, 
whenapplicable)Overall 
radiographic 
response
CR CR No CR ≥4 wks. ConfirmationbCR = Non -PD + no 
focal uptake 
(lesion count = 0)CR
CR CR No CR ≥4 wks. ConfirmationbSD = Non -PD PR
CR CR No CR ≥4 wks. ConfirmationbPD PD
CR Non-CR/non -
PDNo PR ≥4 wks. ConfirmationbCR = Non -PD + no 
focal uptake 
(lesion count = 0)PR
CR Non-CR/non -
PDNo PR ≥4 wks. ConfirmationbSD = Non -PD PR
CR Non-CR/non -
PDNo PR ≥4 wks. ConfirmationbPD PD
CR Not evaluated No PR ≥4 wks. ConfirmationbCR = Non -PD + no 
focal uptake 
(lesion count = 0)PR
CR Not evaluated No PR ≥4 wks. ConfirmationbSD = Non -PD PR
CR Not evaluated No PR ≥4 wks. ConfirmationbPD PD
CR CR No CR ≥4 wks. ConfirmationbNE (i.e. poor scan 
quality, superscan)NE
PR Non-CR/Non -
PD/ not 
evaluatedNo PR ≥4 wks. ConfirmationbCR = Non -PD + no 
focal uptake (lesion 
count = 0)PR
PR Non-CR/Non -
PD/ not 
evaluatedNo PR ≥4 wks. ConfirmationbSD = Non -PD PR
PR Non-CR/Non -
PD/ not 
evaluatedNo PR ≥4 wks. ConfirmationbPD PD
PR Non-CR/Non -
PD/ not 
evaluatedNo PR ≥4 wks. ConfirmationbNE (i.e. poor scan 
quality, superscan)NE
SD Non-PD or 
not all 
evaluatedNo SD SD Any except PD SD
SD Non-PD or 
not all 
evaluatedNo SD SD NE (i.e. poor scan 
quality, superscan)NE
Not all 
evaluatedNon-PD No NE NE Any except PD NE
Not all 
evaluatedNon-PD No NE NE PD PD
Not done NA NA Non-PD NE
PD PD
NE NE
CR CR No CR ≥4 wks. ConfirmationbNot done NE
CR CR No CR ≥4 wks. ConfirmationbNE
CR CR No CR ≥4 wks. ConfirmationbNE
CR Non-
CR/non -PDNo PR ≥4 wks. ConfirmationbNE
CR Non-
CR/non -PDNo PR ≥4 wks. ConfirmationbNE
CR Non-
CR/non -PDNo PR ≥4 wks. ConfirmationbNE
CR Not 
evaluatedNo PR ≥4 wks. ConfirmationbNE
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
94
Approved , Date: [ADDRESS_1044586] v1.1 
response 
(nodal/visceral)Best overall response 
RECIST v1.1 when 
confirmation is 
requiredaOverall PCWG3 
response (bone, 
whenapplicable)Overall 
radiographic 
response
CR Not 
evaluatedNo PR ≥4 wks. ConfirmationbNE
CR Not 
evaluatedNo PR ≥4 wks. ConfirmationbNE
SD Non-PD or 
not all 
evaluatedNo SD SD NE
SD Non-PD or 
not all 
evaluatedNo SD SD NE
Not all 
evaluatedNon-PD No NE NE NE
Not all 
evaluatedNon-PD No NE NE NE
PD Any Yes or 
NoPD PD PD
Any PDcYes or 
NoPD PD PD
Any Any Yes PD PD PD
PD Any Yes or 
NoPD PD Any PD
Any PDcYes or 
NoPD PD Any PD
Any Any Yes PD PD Any PD
CR=complete response; PR=partial response; SD=stable disease; PD=progressive disease; NE=not evaluable; 
wks=weeks
a.See Eisenhauer et al for further details on what is evidence of a new lesion.6
b.Only for non -random ized studies with response as primary endpoint.
c. Unequivocal progression in non -target lesions may be accepted as disease progression.
Note: Subjects with a global deterioration of health status requiring discontinuation of treatm ent without objective 
evidence of disease progression at that time should be reported as “symp tomatic deterioration.” Every effort should 
be made to document the objective progression even after discontinuation of treatment.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
95
Approved , Date: 17 July 2020Attachment 3:ECOG Performance Status
ECOG Grade Scale (with Karnofsky conversion)
0 Fully  active, able to carry  on all predisease performance without restriction. 
(Karnofsky  90-100)
1 Restricted in physically  strenuous activity  but ambulatory  and able to carry  out 
work on a light or sedentary  nature, eg, light housework, office work. (Karnofsky  
70-80)
2 Ambulatory  and capable of all self -care but unable to carr y out an y wo rk activities. 
Up and about more than 50% of waking hours. (Karnofsk y 50-60)
3 Capable of only limited self-care; confined to bed or chair more than 50% of 
waking hours. (Karnofsky 30 -40)
4 Completely  disabled. Cannot carry  on any self-care. Totally  confined to bed or 
chair. (Karnofsk y 10-20)
5 Dead. (Karnofsky  0)
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
96
Approved , Date: 17 July 2020Attachment 4:Medications That Could Potentially Cause QT Prolongation or Torsades De Pointes
Attachment deleted per Protocol Amendment 3.
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
97
Approved , Date: 17 July 2020Attachment 5:Substrates of CYP1A 2
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeli
ng/ucm093664.htm8
http://medicine.iupui.edu/CLINPHARM /ddis/main -table11
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
98
Approved , Date: 17 July 2020Attachment 6:Anticipated Events
Anticipated Event
An anticipated event is an adverse event (serious or non-serious) that commonly occurs as aconsequence 
of the underlying disease or condition under investigation (disease -specific events) or background regimen 
(ADT events).
For the purposes of this study, the following events will be considered anticipated events:
Disease -specific Events ADT Ev ents
erectile dysfunction depression
hematuria gynecomastia
incontinence libido decreased
lymphoedema osteoporosis
nocturia sexual dysfunction
painful ejaculation testicular atrophy
prostatic specific antigen 
increased
ureteric obstruction
urethral obstruction
urinary flow decreased
urinary hesitation
urinary tract obstruction
Reporting of Anticipated Events
All adverse events will be recorded in the CRF regardless of whether considered to be anticipated events
and will be reported to the sponsor as described in Section 12.3.1 , All Adverse Events. Any anticipated 
event that meets SAE criteria will be report ed to the sponsor as described in Section 12.3.2,
 Serious Adverse 
Events. Each anticipated event will be assessed by [CONTACT_762453] -related, will undergo expedited reporting (if appropriate) per applicable clinical trial 
legislation to Health Authorities and IRB/ECs. If an anticipated event is considered disease -related or not 
related to study drug, 
the event will beexempt from expedited reporting . To meet US regulatory clinical 
trial legislation, the sponsor will perform aggregate review of anticipated events as outlined below , and if 
determined to bedrug-related will implement expedited reporting of these events to Health Authorities and 
IRBs/ECs. 
Safety Assessment Committee (SAC)
A Safety Assessment Committee (SAC) will be established to perform reviews of pre-specified anticipated 
events at an aggregate level. The SAC is a safety committ ee within the sponsor’s organization that is 
independent of the sponsor’s study team. The SAC will meet to aid in the recommendation to the sponsor’s
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
99
Approved , Date: 17 July 2020study team as to whether there is a reasonable possibility that an anticipated event is related to the study 
intervention based on a review of the aggregate data.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events Safety 
Monitoring Plan .
JNJ-64091742   (niraparib)
Clinical Protocol 64091742PCR2001 Amendment 8
100
Approved , Date: 17 July 2020Attachment 7:Long -term Extension Phase 
The LTE Phase will begin after completion of the primary  anal ysis and subsequent notification to 
the sites. The sponsor will continue to provide study  drug until subjects no longer derive benefit 
from treatment or until further notification by [CONTACT_142921] a different means for continued 
supply  of study  treatment.
At the time of initiation of the LTE Phase, subjec ts who elect not to continue in the LTE Phase 
will be discontinued from the study within approximately  3 months from the initiation of the LTE 
Phase at the site. Subjects who progress and are no longer deriving clinical benefit and require 
subsequent treatment will be discontinued from the study  and will receive such treatment at the 
discretion of the investigator. 
The LTE Phase will begin when both Amendment 8 is approved at the site and the sponsor has 
notified the site of the start of the LTE.
Subjects who are still receiving niraparib will be offered the option to continue to receive 
niraparib.
Subjects who are in the Follow -up Phase of the main study  will be discontinued from the study 
and all data collection will cease.
Subjects must provide updated informed consent (signed form or remote) to continue in the 
LTE Phase of the stud y. 
Study Treatment Administration
Study T reatment During the L ong-term Extension
Study  treatment will be administered orally  on an outpatient basis . Atreatment cycle is defin ed as 
28days. Sufficient study  drug for each treatment cy cle will be distributed as specified in Table 7. 
Subjects will receive niraparib according to the schedule in
 Table 6.If a subject was receiving a 
lower dose of niraparib, he should continue on that lower dose in the LTE Phase.
Table 6: Study Treatment Administration for the Long- term  Extension Phase
Study Treatment Daily Dose Schedule
Niraparib 300mg (3×100 mgtablets) Once daily with or without food
If a dose of niraparib is missed, the dose should only be replaced if the subject remembers and 
takes the dose within a 12 -hour window; otherwise, it should be omitted and should not be made 
up or taken with the next dose the following day . 
Dose modifications for toxicity  are provided in Section 6.2 of the protocol.
Prohibit ions and Restrictions
Refer to protocol Sections 8.1and 8.2for prohibited and restricted concomitant medication s
.